

# BMJ Open

## A randomized controlled trial to evaluate the impact of sexual-health-clinic-based automated text message reminders on the testing of HIV and other sexually transmitted infections in men who have sex with men in China: protocol for the T2T Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015787
Article Type:	Protocol
Date Submitted by the Author:	02-Jan-2017
Complete List of Authors:	Zou, Huachun; Sun Yat-sen University, School of Public Health Meng, Xiaojun; Wuxi Municipal Center for Disease Control and Prevention, Department of Infectious Disease Control Grulich, Andrew; The Kirby Institute, UNSW, Huang, Shuijie; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office Jia, Tianjian; Wuxi Municipal Center for Disease Control and Prevention, Department of Infectious Disease Control Zhang, Xuan; Wuxi Municipal Center for Disease Control and Prevention, Department of Infectious Disease Control Luo, Zhenzhou; Nanshan District Center for Chronic Disease Control and Prevention, STD Control Office Ding, Yi; Nanshan District Center for Chronic Disease Control and Prevention, STD Control Office Yang, Ligang; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office Huang, Jinmei; Guangdong Provincial Center for Skin Diseases and STDs Control, Chen, Weiyang; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office zheng, heping; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office Yang, Bin; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Health services research, Health policy, Sexual health
Keywords:	Text message service, Reminder, HIV, STI, Men who have sex with men, Sexual health clinic

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-015787 on 10 July 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**A randomized controlled trial to evaluate the impact of  
sexual-health-clinic-based automated text message reminders on the  
testing of HIV and other sexually transmitted infections in men who  
have sex with men in China: protocol for the T2T Study**

Huachun Zou<sup>1,2,3#\*</sup>, Xiaojun Meng<sup>4#</sup>, Andrew Grulich<sup>3</sup>, Shujie Huang<sup>2</sup>, Tianjian Jia<sup>4</sup>,  
Xuan Zhang<sup>4</sup>, Zhenzhou Luo<sup>5</sup>, Yi Ding<sup>5</sup>, Ligang Yang<sup>2</sup>, Jinmei Han<sup>2</sup>, Weiyang Chen<sup>2</sup>,  
Heping Zheng<sup>2</sup> and Bin Yang<sup>2\*</sup>

1. School of Public Health, Sun Yat-sen University, Guangzhou, China
2. STD Control Office, Guangdong Provincial Center for Skin Disease and STI Control, Guangzhou, China
3. Kirby Institute, University of New South Wales, Sydney, Australia
4. Department of Infectious Disease Control, Wuxi Municipal Center for Disease Control and Prevention, Wuxi, China
5. STD Control Office, Nanshan District Center for Chronic Disease Control and Prevention, Shenzhen, China

**# Huachun Zou and Xiaojun Meng contributed equally to this paper**

**Corresponding authors**

Dr. Huachun Zou

School of Public Health, Sun Yat-sen University, Guangzhou, China

Email: zouhuachun@mail.sysu.edu.cn

Dr. Bin Yang

Guangdong Provincial Center for Skin Disease and STI Control, Guangzhou, China

Email: yangbin101@hotmail.com

## ABSTRACT

**Introduction:** The frequency of screening for HIV and other sexually transmitted infections (STIs) among men who have sex with men (MSM) is still low in China.

**Methods and analysis:** A sexual health clinic (SHC)-based randomized controlled trial will be conducted in Guangzhou, Wuxi and Shenzhen, China, enrolling 600 MSM. Eligibility will be judged by the pre-programed iPad-based questionnaire: 1) be  $\geq 18$  years of age, and 2) have had 2 or more male anal sex partners, or condomless anal sex with a casual male sex partner, or an STI history, in the past 6 months, and 3) provide a valid mobile number. Eligible men will be randomly allocated 1:1 to either Intervention Arm (with monthly text message reminding them to test for HIV/STIs) or Control Arm (without reminder). Men in both arms will complete a questionnaire onsite at enrollment and 12 months, and another questionnaire online at 6 months. Men in both arms will be tested for HIV, syphilis, anal gonorrhoea/chlamydia, and penile gonorrhoea/chlamydia at enrollment and 12 months. The primary outcome is the rate and frequency of HIV testing within the 12 months after enrolment. The secondary outcome is the rate of unprotected anal intercourse. An assessment of the cost-effectiveness of this intervention is also planned.

**Ethics and dissemination:** The study has been approved by the Ethical Review Committees of the University of New South Wales in Australia (HC16803), the Guangdong Provincial Center for Skin Disease and STI Control (GDDHLS-20160926) and Wuxi Center for Disease Control and Prevention (WXCDC2016009) in China. Study findings will be submitted to academic journals and disseminated to local health authorities.

**Trial registration number:** This study has been registered at the Chinese Clinical Trial Registry (<http://www.chictr.org.cn/enIndex.aspx>) and WHO International Clinical Trials Registry Platform (<http://www.who.int/ictrp/en/>), ID: ChiCTR-IPR-15006086.

### Keywords

Text message service; Reminder; HIV; STI; Men who have sex with men; Sexual

1  
2  
3 health clinic  
4  
5  
6

## 7 **ARTICLE SUMMARY**

### 10 **Strengths and limitations of this study**

- 14 ■ No study has examined the role of sexual health clinic based automated short  
15 messaging services in the testing and detection of HIV/STIs in men who have sex  
16 with men (MSM) in China.
  - 17 ■ Findings from this study has the potential to help health authorities to develop new  
18 interventional strategies to control HIV/STIs among MSM in China.
  - 19 ■ This intervention, from judging eligibility to sending text message reminders, is  
20 wholly automated and requires limited human input, which can be easily replicated  
21 in other sexual health clinics in China and beyond.
  - 22 ■ Sexual behaviours and STI history during follow-up will be self-reported by  
23 participants, which may be subject to bias.
  - 24 ■ Loss to follow-up of participants is possible in this longitudinal study.
- 25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Men who have sex with men (MSM) in many countries are disproportionately affected by HIV and other sexually transmissible infections (STIs) such as gonorrhoea, chlamydia and syphilis<sup>1-4</sup>. More frequent screening for HIV and other STIs has the potential to improve detection of these largely asymptomatic infections, interrupting transmission and improving disease control<sup>5</sup>. Guidelines in a number of countries call for regular screening for HIV/STIs among MSM. For example, the US and Australian guidelines recommend that all MSM be screened for urethral and rectal chlamydia, pharyngeal and rectal gonorrhoea, syphilis and HIV at least once a year, with 3-6 monthly screening of MSM at higher-risk for HIV/STIs transmission<sup>6,7</sup>. However, available data suggest that the rate of screening for these infections among MSM is much lower than recommended in many countries<sup>8,9</sup>.

Significant increases in screening rates for gonorrhoea and chlamydia (Odds ratio (OR) range:1.4-1.9) have been demonstrated in observational studies using several different strategies: use of a computer alert on an electronic medical record<sup>10</sup>, the introduction of clinic guidelines on STI screening<sup>11</sup>, and short text messaging reminders for repeat STI screening<sup>12</sup>. Increases in syphilis testing (OR range: 2.3-21.4) were found using the following strategies: advocating regular serological screening for syphilis during routine HIV care<sup>13</sup>; including syphilis serology testing routinely with blood tests performed as part of HIV monitoring<sup>14</sup>; use of a computer alert on an electronic medical record<sup>15</sup>; and an electronic medical record system with a reminder to clinicians to enhance syphilis retesting following syphilis treatment<sup>16</sup>. A

1  
2  
3  
4 before-and-after study in Australia using existing clinical and behavioral data of  
5  
6 clients attending a major sexual health clinic (SHC) found that automated,  
7  
8 computer-generated text message service (SMS) 3-monthly reminders doubled the  
9  
10 testing rate for HIV, syphilis, gonorrhoea and chlamydia among MSM <sup>17</sup>. That study  
11  
12 also demonstrated an increased detection rate for syphilis, gonorrhoea and chlamydia,  
13  
14 but not for HIV <sup>17</sup>. Another before-and-after study in Australia found increased  
15  
16 HIV/STI re-testing rates among MSM as a result of 3-6 monthly SMS reminders at a  
17  
18 large SHC <sup>12</sup>. However until now there has been no randomized controlled trial to  
19  
20 confirm these effects.  
21  
22  
23  
24

25  
26 MSM in China are increasingly engaging in high risk sexual behaviors such as low  
27  
28 rate of condom use in anal sex, multiple concurrent partnerships and drug use during  
29  
30 sex <sup>18</sup>. The rates of HIV and STIs among this population are high and increasing. The  
31  
32 estimated HIV prevalence among MSM in China increased sharply over the past  
33  
34 decade: from 0.6% in 2003 to 8% in 2015 <sup>19 20</sup>. Accordingly the proportion of MSM  
35  
36 among all people living with HIV/AIDS also climbed steadily: from 7% in 2005 to 25%  
37  
38 in 2015 <sup>21 22</sup>. Many MSM in China were also infected with other STIs. A  
39  
40 meta-analysis found that the prevalence levels of STIs among MSM in China were 6%  
41  
42 for chlamydia, 2% for genital warts, 2% for gonorrhoea, 9% for hepatitis B, 1% for  
43  
44 hepatitis C, 66% for human papillomavirus and 11% for herpes simplex virus-2  
45  
46 <sup>23</sup>. However the testing rate for these infections was suboptimal. A systematic review  
47  
48 found that less than 40% of MSM in China had tested for HIV in the past year <sup>24</sup>.  
49  
50 Nearly half of MSM in China had a baseline CD4+ Cell count  $\leq 350$  per mm<sup>3</sup> at  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 HIV diagnosis<sup>25</sup>. The rates of testing for other STIs were also low<sup>26 27</sup>. It is urgently  
5  
6  
7  
8  
9  
10 needed to introduce an effective intervention that can increase testing and help  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

achieve timely diagnosis of HIV and other STIs among MSM in China.

Our study aims to use a randomized controlled trial to evaluate the role of SHC-based automated text message services in the testing and detection of HIV and other STIs among MSM in China.

## METHODS AND ANALYSIS

### Overview

The proposed protocol was developed and facilitated by collaborations between experienced investigators from the Kirby Institute, the University of New South Wales (UNSW) in Sydney, Australia, Guangdong Center for Skin Disease & STI Control (GCSDSC) in Guangzhou, China, Wuxi Center for Disease Control and Prevention (CDC) in Wuxi, China, Nanshan District Center for Chronic Disease Control and Prevention (CCDC) in Shenzhen, China, and Sun Yat-sen University in Guangzhou, China. The study will randomize 600 men who have sex with men (MSM) 1:1 into Intervention Group (with reminders) and Control Group (without reminders) and evaluate the role of SHC-based automated text message services in the testing and detection of HIV/STIs among MSM. A sample size of 300 MSM in each group will provide 90% power to detect a 15.0% (from 50% to 65%) difference in the proportion of HIV testing in the past 12 months between the two groups, considering 30% of loss-to-follow-up at 12 months.



## Objectives

The primary objective of this study is to determine the impact of SHC-based automated text message services on the testing and detection of HIV. The secondary objective is to determine the impact of SHC-based automated text message services on change in sexual behaviors. The additional analysis is to evaluate the costs and incremental cost-effectiveness of the intervention.

## Study settings

This study will be based at the SHCs affiliated to GCSDSC, Wuxi CDC and Shenzhen Nanshan CCDC. The population in Guangzhou, Wuxi and Shenzhen was around 13, 6 and 13 million, respectively, all with per capita gross domestic product (GDP) of over USD20,000 in 2014<sup>28 29</sup>. The three SHCs provide HIV/syphilis voluntary counseling and testing (VCT) and HIV/STI treatment services to over 25,000 clients annually, 10% of whom were estimated to be MSM (data not published). These three SHCs are equipped with microbiological diagnostic units and capable of timely testing and treating HIV and other STIs, including syphilis, gonorrhoea, chlamydia trachomatis and genital warts.

## Inclusion criteria

MSM attending the three clinics will be invited to join the study if they meet the following criteria: 1) anatomical men aged 18 years or older; 2) having over 2 male

1  
2  
3  
4 anal sex partners, or condomless anal sex with a casual male sex partner, or an STI  
5  
6 history, in the past 6 months; 3) possessing a mobile phone; 4) willing to provide  
7  
8 informed consent for the collection of demographics, sexual behaviors and HIV/STI  
9  
10 testing experiences and biological samples to test for HIV/STIs; 5) residing in a study  
11  
12 city in the next 12 months or visiting a study city frequently enough to participate in  
13  
14 the study; 6) willing to register testing results if they test elsewhere during the study.  
15  
16  
17  
18  
19

### 20 21 **Study procedures**

22  
23 Besides MSM attending the SHC affiliated to GCSDSC, in Guangzhou we will also  
24  
25 work with local community clinics to refer MSM to attend the study. A study phone  
26  
27 number will be designated to this study. This randomized controlled trial will consist  
28  
29 of computer-assisted self-interview (CASI) and automated, computer-generated SMS  
30  
31 reminders among 600 MSM attending the SHCs. It will be conducted over 21-24  
32  
33 months: 3 months of logistic preparation, 3-6 months of recruitment, 12 months of  
34  
35 follow up and 3 months of report preparation. Detailed recruitment procedure is  
36  
37 described in Figure 1. Over a 3-6 months recruiting period, all male clients presenting  
38  
39 to the clinic will be given an information flyer by a receptionist who is not directly  
40  
41 involved in the study. The flyer will include basic information about the study,  
42  
43 including that it is a study for MSM. The receptionist will ask each male client to read  
44  
45 the flyer and to visit the study research assistant who sits at a nearby desk, if they are  
46  
47 interested in finding out more about the study. Those male clients who express interest  
48  
49 in participating will see the study research assistant, who will take them to a private  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 clinic room where an iPad questionnaire system is installed. The study research  
5  
6 assistant will explain what the study involves and go through the iPad-based full  
7  
8 Participant Information and Consent Form (PICF) with potential eligible participants.  
9  
10  
11 Men will have time to read the PICF, to ask questions, and to decide if they will  
12  
13 participate in the study. Men will need to click the “Agree” button to consent before  
14  
15 completing an iPad-based questionnaire. The study research assistant will ask  
16  
17 consented participants to complete the iPad-based questionnaire on their own, in the  
18  
19 private room. They will be instructed that if they have any further questions, they  
20  
21 should ask the research assistant who will be at a desk, outside of the private room.  
22  
23 The questionnaire will collect information on sexual behaviours, HIV/STI testing  
24  
25 behaviours and diagnosis history and alcohol/tobacco/drug use. The pre-programmed  
26  
27 logic in the questionnaire will judge if a participant is actually eligible, based on  
28  
29 sexual behavior variables. Those who are not eligible will be thanked and released  
30  
31 back into the clinic waiting room for their routine clinical care. Eligible participants  
32  
33 will provide a valid mobile phone number and then be automatically randomised into  
34  
35 either intervention or control group, by the computer. They will then receive a text  
36  
37 message with a code as their Study ID. When they finish the PICF and questionnaire  
38  
39 participants will see the study research assistant who will guide them to see a doctor  
40  
41 for bio-specimen collection, followed by routine clinical care, if necessary. Eligible  
42  
43 MSM who opt out of the study will be recorded and asked about reasons to decline.  
44  
45  
46  
47  
48  
49  
50  
51  
52

53  
54 Detailed study procedure is described in Figure 2. We acknowledge that directly  
55  
56 mentioning of sensitive words such as HIV and STIs in SMS reminders may lead to  
57  
58  
59  
60

1  
2  
3  
4 the exposure of privacy of participants to others. As a result, we will avoid using these  
5  
6 sensitive words in actual SMS reminders. Instead, in actual reminders we will use  
7  
8 “*Little A*” to refer to “HIV”, “*Little B*” to refer to “STIs”, “*Health check*” to refer to  
9  
10 “HIV/STI testing” and “*Self health check*” to refer to “HIV self-testing at home”. We  
11  
12 will clarify this in the PICF. All messages will include a withdrawal option.  
13  
14

15  
16 For MSM in the Intervention Group, upon enrolment, they will receive Message A:  
17  
18 “A gentle reminder: If you plan to have a health check again in the next 12 months,  
19  
20 welcome to our center. If you do it elsewhere (including self-health check) in the next  
21  
22 12 months, please register the results online at the following link: \*\*\*\*\*. Every time  
23  
24 you register we will compensate you with an electronic mobile phone credit of  
25  
26 CNY10 (USD1.5). If you change your mobile phone number in the next 12 months  
27  
28 please let us know.” When they register online, participants need to enter the mobile  
29  
30 phone number that was validated at enrolment and the initial of their surname to enter  
31  
32 the questionnaire. This is designed to avoid the exposure of sensitive questions to a  
33  
34 non participant. On the second day after enrolment, they will receive Message B: “A  
35  
36 gentle reminder: Little A and little B are spreading rapidly and it’s hard to detect by  
37  
38 yourself. Your best protection is a regular check-up (e.g. every 3 months). If you  
39  
40 change your mobile phone number please let us know.” Starting from day 30, they  
41  
42 will receive Message C every 30 days: “A gentle reminder: If you have not had a  
43  
44 health check in the past 3 months please do so as soon as possible. If you change your  
45  
46 mobile phone number please let us know.” On day 190, 10 days after they receive  
47  
48 Message C on day 180, they will receive Message D, reminding them to complete an  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 online survey about their sexual life and testing behaviors in the past 6 months: “A  
5  
6 gentle reminder: please complete a survey at the following link at your earliest  
7  
8 convenience: \*\*\*\*\*. We will compensate you with an electronic mobile phone credit  
9  
10 of CNY50 (USD8). If you change your mobile phone number please let us know.” On  
11  
12 day 370, 10 days after they receive Message C on day 360, they will receive Message  
13  
14 E, reminding them to complete an onsite survey about their sexual life and testing  
15  
16 behaviours in the past 6 months: “A gentle reminder: please attend our center to  
17  
18 complete the final survey. We will compensate you with an electronic mobile phone  
19  
20 credit of CNY100 (USD16), together with condoms, lubricant and health booklets. If  
21  
22 you change your mobile phone number please let us know.” At enrollment and 12  
23  
24 months men will be tested for HIV, syphilis, urethral and anal chlamydia and  
25  
26 gonorrhoea, and examined for anogenital warts. CD4+ testing will be provided for  
27  
28 men diagnosed with HIV. HIV/STIs will be treated as per relevant treatment  
29  
30 guidelines in China. At 6 and 12 months men will also be asked questions about their  
31  
32 experience of the intervention including the impact of the intervention on their  
33  
34 everyday life, mental health, sexual health and general health (Figure 2).  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 MSM in the Control Group will receive Message A upon enrolment, Message D on  
45  
46 day 190 and Message E on 370. They will not receive Messages B and C. They will  
47  
48 complete the same questionnaire as men in the intervention group do at enrolment, 6  
49  
50 months and 12 months and test for above-mentioned HIV/STIs at enrolment and 12  
51  
52 months. They will not be asked about their experience of the intervention.  
53  
54  
55

56 The 10 days' time gap between Messages C and D is planned to give men in both  
57  
58  
59  
60

1  
2  
3  
4 groups enough time to attend a SHC upon receiving Message C. Besides men's  
5  
6 mobile phone number (compulsory) we will also try to collect other contact  
7  
8 information (optional), including email, QQ and WeChat ID (instant online messaging  
9  
10 applications frequently used in China). At 6 and 12 months, men will be contacted  
11  
12 with the additional contact information if they do not complete a designated survey  
13  
14 within 7 days after Messages D and E are sent. Men who register testing information  
15  
16 online or fill in an online questionnaire at 6 months will need to enter their mobile  
17  
18 number to access the actual questionnaire. This is designed in case another person  
19  
20 oversees the URL address from Message A. The process from commencing CASI to  
21  
22 the regular dispatch of the reminders will be entirely automated, requiring no human  
23  
24  
25  
26  
27  
28  
29 input.

30  
31 For men in both groups, at enrolment and 12 months, a study nurse will collect a  
32  
33 swab from the anal canal to test for anal gonorrhoea and chlamydia, and 5 ml of blood  
34  
35 to test to test for HIV and syphilis. Participants will self-collect a urine sample to test  
36  
37 for urethral gonorrhoea and chlamydia. A doctor will check ano-genital warts for each  
38  
39 participant. The HIV serologic status will be screened by ARCHITECT HIV Ag/Ab  
40  
41 Combo assay (Abbott Laboratories, Abbott Park, Illinois, USA). Positive samples will  
42  
43 be further screened by enzyme linked immunosorbent assay (ELISA) (Bio-Rad  
44  
45 Laboratories, CA, USA). Samples positive for ELISA will be confirmed by the  
46  
47 HIV-1/2 Western blot assay (HIV Blot 2.2 WB; Genelabs Diagnostics, Singapore).  
48  
49 Confirmed HIV cases will be tested for CD4+ T Cell count. Syphilis will be screened  
50  
51 by the toluidine red unheated serum test (TRUST) (RSbio, Shanghai, China) and  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 samples positive for TRUST will be confirmed by treponema pallidum particle assay  
5  
6 (TPPA) (Fuji ReBio, Tokyo, Japan). Anal and urethral gonorrhoea and chlamydia will  
7  
8 be tested using polymerase chain reaction (PCR) (Roche Diagnostics, Shanghai,  
9  
10 China). Ano-genital warts will be checked by a doctor with the assistance of acetic  
11  
12 acid test.  
13  
14

### 15 16 17 18 19 **Incentives and retention**

20  
21 Study participants will receive health education materials, condoms and lubricant  
22  
23 upon completion of the CASI questionnaire at enrolment and 12 months. Participants  
24  
25 will receive an electronic mobile phone credit of CNY50 (USD8), CNY50 (USD8)  
26  
27 and CNY100 (USD16), upon completion of the surveys at enrolment, 6 months and  
28  
29 12 months. Participants who test elsewhere will receive an additional electronic  
30  
31 mobile phone credit CNY 10 (USD 1.5) each time they register testing results online.  
32  
33  
34  
35  
36  
37  
38

### 39 **Statistical methods**

#### 40 41 ***Power/sample size***

42  
43 We used the following formula to calculate sample size:  
44

$$45 \quad n = \frac{(Z_{\alpha} \sqrt{2pq} + Z_{\beta} \sqrt{p_0q_0 + p_1q_1})^2}{46 \quad (p_1 - p_0)^2}$$

47  
48 In this formula,  $Z_{\alpha}$  and  $Z_{\beta}$  represent the Z boundaries under the standard normal  
49  
50 distribution;  $p_1$  and  $p_0$  represents proportion of a parameter in the intervention group  
51  
52 and control group, respectively;  $p$  equals to the average of  $p_1$  and  $p_0$ ;  $q=1-p$ . We used  
53  
54  
55  
56  
57  
58 2 parameters in the calculation of sample size: (a) proportion of men who have HIV  
59  
60

1  
2  
3  
4 testing during the 12 months after baseline; (b) proportion of men who have  
5  
6 condomless anal sex during the 12 months after baseline. We assumed a two-sided  
7  
8 hypothesis test with a 5% significance level ( $Z_{\alpha/2}=1.96$ ), a desired power of 90%  
9  
10 ( $Z_{\beta}=1.28$ ), and that both groups will have the same number of observations.

11  
12  
13  
14 Using parameter (a), the rate of HIV testing in the past 12 months among MSM in  
15  
16 Wuxi in 2014 was 50% ( $p_0$ ), and this figure was expected to increase to 65% ( $p_1$ )  
17  
18 according to a before-and-after study in Australia<sup>17</sup>. This resulted in a sample size of  
19  
20 225 in each group. Khosropour et al., retained around 70% of MSM for 12 months  
21  
22 using bimonthly follow-up surveys through text messages<sup>29</sup>. We will adopt a  
23  
24 number of strategies to minimize the loss-to-follow-up rate: educating investigators  
25  
26 about the culture in MSM community and develop rapport with participants;  
27  
28 verifying mobile number at enrolment; contacting participants on days 190 and 370  
29  
30 using various messaging softwares/apps such as WeChat, QQ, email, etc; and  
31  
32 reasonable incentives. Considering a loss-to-follow-up rate of 30%, a sample size of  
33  
34 300 MSM in each group will be needed.  
35  
36  
37  
38  
39  
40  
41  
42  
43

#### 44 *Analysis plan*

45  
46 Analyses will be performed using STATA 13.0 (College Station, TX, USA)  
47  
48 statistical analysis software. All effects will be estimated with a 95% confidence  
49  
50 intervals and p-values from the corresponding hypothesis tests. Statistical  
51  
52 significance will be taken as two sided p-value less than 0.05, with no adjustment for  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 multiple comparisons. Characteristics of groups will be summarized at baseline and  
4  
5 across study arms. Mean duration of study follow-up will be compared by group.  
6  
7

8  
9 Primary analysis will compare randomized groups of MSM using an intention to  
10  
11 treat approach. Initial analyses will be simple, unadjusted comparisons of  
12  
13 randomised groups. If there appears to be any important imbalances between  
14  
15 randomised groups in terms of baseline covariates, adjusted analyses will also be  
16  
17 performed.  
18  
19

20  
21 For the comparison of HIV/STIs testing and detection between the two groups at  
22  
23 the end of the study: 1) we will use Cox proportional hazard models with Kaplan  
24  
25 Meier plots and log-rank test to explore the cumulative rate of reported HIV/STIs  
26  
27 testing and detection during the previous 12 months, comparing the two groups.  
28  
29 Number of testing and detection of each infection will also be compared. 2) we will  
30  
31 use Chi-square test to compare the proportion of reported HIV/STIs testing and  
32  
33 detection during the previous 12 months before intervention with that during the 12  
34  
35 months after intervention, within Intervention Group. Number of testing and  
36  
37 detection of each infection will also be compared.  
38  
39  
40  
41  
42

43  
44 For the comparison of behavioural change between the two groups at the end of  
45  
46 the study: 1) we will use Chi-square test to compare the proportion of reported  
47  
48 condomless anal sex during the previous 12 months between the two groups. 2) we  
49  
50 will use rank sum test to compare the number of reported anal sex partners during  
51  
52 the previous 12 months between the two groups. 3) we will use Chi-square test to  
53  
54 compare the proportion of reported condomless anal sex during the previous 12  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 months before intervention with that during the 12 months after intervention, within  
5  
6 Intervention Group. 4) we will use rank sum test to compare the number of reported  
7  
8 anal sex partners during the previous 12 months before intervention with that during  
9  
10 the 12 months after intervention, within Intervention Group.  
11  
12

### 13 14 15 16 **Additional analyses**

#### 17 18 *Cost and cost-effectiveness evaluation*

19  
20 Although some studies have assessed the cost-effectiveness of HIV testing methods  
21  
22 among high-risk populations in some regions <sup>31-37</sup>, whether the intervention in this  
23  
24 study is cost-effective is unclear. As a result, the costs and incremental  
25  
26 cost-effectiveness of the intervention compared to control will be evaluated, using  
27  
28 standard methods of cost-effectiveness analysis <sup>38</sup>. Our analysis will include the  
29  
30 costs of the self registration and SMS reminding system development and  
31  
32 maintenance, HIV/STI testing and counseling, follow-up, and treatment. All costs  
33  
34 will be measured from a societal perspective, and inflated to 2015 Chinese Yuan at a  
35  
36 discounting rate of 3% annually.  
37  
38  
39  
40  
41  
42  
43  
44  
45

#### 46 47 *Cost-Effectiveness analysis*

48  
49 Based on incremental cost-effectiveness analysis, we will calculate the incremental  
50  
51 cost for one additional newly identified HIV/STI case, and one additional early HIV  
52  
53 case, using the following formula <sup>38</sup>:  
54

$$55 \quad ICER_{ij} = (C_i - C_j) / (E_i - E_j)$$

56  
57  
58  
59  
60

### *Markov model based Cost-Utility analysis*

We will develop a decision model to reflect when successful HIV/STI detection, follow-up, and treatment occur for a cohort of MSM with/without intervention, and then a Markov model estimating the lifecycle of MSM from entering the cohort until death, to examine the incremental cost-utility of intervention. Effectiveness is measured as quality adjusted life-years (QALYs) gained. We assume that QALYs accrues by early initiation of antiretroviral therapy (ART) following early HIV detection. According to the actual situation in China, the natural history of HIV/AIDS is categorized as the following stages: asymptomatic HIV, symptomatic HIV, AIDS and death. Health states summarizes current status based on CD4+ T cell count, quality of life, ART usage and resource use. ART and CD4+ T cell count combined determines the transition probabilities and mortality rates<sup>39 40</sup>. The model will assess HIV status, stage transfer and its consequences among MSM with incident HIV infection on an annual basis. All the parameters used in this model will be compiled from a variety of sources, including literature review, ongoing cohort studies and investigations, surveillance data or unpublished data from Wuxi and other parts of China.

In this study, we assume that: (1) stage transition in the Markov model happens once a year, (2) once an HIV infected man receives ART, he will complete the entire treatment procedure. To account for assumptions and uncertainties of this model, we will perform one-way sensitivity analyses on all model parameters. For all the

1  
2  
3  
4 probability variables, our ranges for sensitivity analyses represent our judgment of  
5  
6 the variation on the basis of both the literature and discussion with experts.  
7  
8  
9

### 10 11 **Sample/data storage** 12

13  
14 All electronic questionnaires, consent forms will be stored in a password-protected  
15  
16 computer at the information center at GCSDSC as per its common practice. The data  
17  
18 will be stored in a format that is identifiable. This is designed to match data with  
19  
20 individual participants in follow-up visits in this study. However, only the custodian  
21  
22 will have access to the original data. All identifying variables, including name (a  
23  
24 pseudonym is ok), initial of participant's surname, mobile phone number and date of  
25  
26 birth, will be de-identified before data are transferred to a data analyst in this study.  
27  
28  
29 The custodian will ensure that data is stored and managed appropriately and  
30  
31 according to the relevant privacy laws. The data custodian will only share data with  
32  
33 researchers who are conducting HIV/STI testing related epidemiologic studies and  
34  
35 only once these projects have received separate ethics approval from a Human  
36  
37 Research Ethics Committee. All identifying variables, including name (a pseudonym  
38  
39 is ok), initial of participant's surname, mobile phone number and date of birth, will  
40  
41 be de-identified before data sharing. Bio-specimen collected at a given site will be  
42  
43 stored at the corresponding participatory institution.  
44  
45  
46  
47  
48  
49  
50

### 51 52 53 54 **ETHICS AND DISSEMINATION** 55

56  
57 The study has been approved by the Ethical Review Committees of the University of  
58  
59  
60

1  
2  
3  
4 New South Wales in Australia (HC16803), the  
5  
6 Guangdong Provincial Center for Skin Disease and STI Control  
7  
8 (GDDHLS-20160926) and Wuxi Center for Disease Control and Prevention  
9  
10 (WXCDC2016009) in China. We anticipate that the benefits of study participation  
11  
12 will outweigh any risks, including loss of confidentiality and privacy of clinical  
13  
14 information. Participants will benefit from frequent testing and early diagnosis of  
15  
16 HIV/STIs and timely treatment if positive. The findings of the study will be  
17  
18 disseminated to local and national government in China as well as the wider  
19  
20 academic audience and public health organizations through peer-reviewed  
21  
22 publications and international conferences.  
23  
24  
25  
26  
27  
28  
29  
30

## 31 **DISCUSSION**

32  
33 This study protocol describes a randomized controlled trial designed to increase the  
34  
35 testing and detection of HIV and other STIs among Chinese MSM through  
36  
37 computer-assisted self-interview and automated computer generated reminders.  
38  
39 Firstly, we seek to develop a platform requiring limited investment and human  
40  
41 power that could be easily replicated and deployed in other SHCs in China and  
42  
43 beyond. As such, one of the challenges in designing the intervention was the  
44  
45 acceptance of it among target population-MSM in China-a population that has long  
46  
47 been marginalized and discriminated against. Fortunately in our unpublished  
48  
49 pre-trial study, almost 80% of MSM in the community were willing to take such an  
50  
51 intervention. It is estimated that this rate would be even higher among MSM  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 attending SHCs. Other key challenges to this study include the need to sustain the  
4 motivation of clinic staff to participate in the study while addressing the multiple  
5 competing health priorities. Secondly, we will be able to understand MSM with what  
6 characteristics are more likely to take this intervention and barriers that prevent other  
7 MSM from taking this intervention. This will help develop an intervention that is  
8 contextualized and tailored to the characteristics of MSM. Thirdly, if successful, this  
9 intervention with high potential cost-effectiveness will contribute to the compilation  
10 of the fabric of quality SHCs and health providers that will eventually be readily  
11 available to MSM at their finger tips. This will greatly encourage and facilitate them  
12 to test for HIV/STIs on a more frequent basis. Lastly, results from this study may  
13 facilitate the development of proactive interventions strategies targeting other at-risk  
14 populations, such as female sex workers and their clients, and drug users, etc. to  
15 increase the testing and detection of HIV and other STIs and hence prevent the  
16 transmission of these infections.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 This intervention has its limitations: Firstly, the 12-months research period is a  
40 long commitment for MSM as many of them are quite mobile. The retention rate  
41 could be compromised by 12 months. To tackle this problem we will verify  
42 participants' mobile phone number at enrolment and remind them to update their  
43 mobile number every 30 days. Additionally we will also use other contact  
44 information reported by participants to achieve the highest possible retention rate.  
45  
46 Secondly, men could forget to register testing experience from other venues. To  
47 tackle this problem, we will remind them to do this in Message A at enrolment.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Because a similar reminder during the study would potentially bring about  
5  
6 contamination to the intervention, we will not send further reminders. Thirdly, as  
7  
8 this intervention will be conducted in metropolitan cities, the results may not apply  
9  
10 to that in other settings.  
11  
12

13  
14 In summary the knowledge gained from this study may be used to design similar  
15  
16 protocols with a higher number of participants and appropriate intervention  
17  
18 strategies to reduce the burden of HIV and other STIs among MSM, a population  
19  
20 who is heavily burdened by these infections. Additionally, if the results are positive,  
21  
22 we will scale up this practice in more SHCs across China.  
23  
24  
25  
26  
27  
28

### 29 **Acknowledgments**

30  
31 We thank Dr. Qianqian Xin from the Capital Institute of Pediatric in Beijing, Dr. Gang  
32  
33 Zeng from Alere Inc Beijing and Dr. Jinghua Li from Sun Yat-sen University for their  
34  
35 comments to the protocol.  
36  
37  
38  
39

### 40 **Authors' contribution**

41  
42 Huachun Zou and Xiaojun Meng initiated this research plan and designed this  
43  
44 protocol with Bin Yang and Andrew Grulich consulting on ethics and feasibility of  
45  
46 the research. Zhenzhou Luo, Tianjian Jia, Xuan Zhang, Yi Ding and Ligang Yang  
47  
48 provided expertise on recruitment and sample collection and will supervise these  
49  
50 aspects at the three study clinics. Jinmei Huang, Shujie Huang and Heping Zheng  
51  
52 provided expertise on sample testing and storage. Weiyong Chen helped with the  
53  
54 design of questionnaire and recruitment methods.  
55  
56  
57

### 58 **Funding**

This work was supported by a grant from Australian National Health and Medical Research Commission (NHMRC) Early Career Fellowship (APP1092621) and research grants from Guangdong Provincial Center for Skin Disease and STI Control (YCS201669), Wuxi municipal health and Family Planning Commission (MS201613), Wuxi Municipal Science and Technology Bureau (CSZ0N1512) and Nanshan District Center for Chronic Disease Control and Prevention. The funding bodies other than NHMRC participated in study design, data collection and analysis, preparation of the manuscript, and the decision to publish.

### Competing interests

All authors declare no competing interests.

### References

1. Public Health Laboratory System. Increased transmission of syphilis in Brighton and Greater Manchester among men who have sex with men. *CDR Wkly* 2000;10:383–386.
2. Victorian Department of Human Service. Sexually transmissible infections. *Victorian Infectious Diseases Bulletin* 2007;10:16–22.  
[http://www.health.vic.gov.au/data/assets/pdf\\_file/0018/48222/vidbv10i1.pdf](http://www.health.vic.gov.au/data/assets/pdf_file/0018/48222/vidbv10i1.pdf). (accessed on 23 June, 2011).
3. Vodstrcil LA, Fairley CK, Fehler G, et al. Trends in Chlamydia and Gonorrhoea Positivity among Heterosexual Men and Men who have sex with Men attending a large urban sexual health service in Australia, 2002–2009. *BMC Infect Dis*. 2011;11:158.
4. Zhang L, Chow EP, Jing J, et al. HIV prevalence in China: integration of surveillance data and a systematic review. *Lancet Infect Dis*. 2013;13:955–963.
5. Zou H, Fairley CK, Guy R, et al. The efficacy of clinic-based interventions aimed at increasing screening for bacterial sexually transmitted infections among men who have sex with men: a systematic review. *Sex Transm Dis*. 2012;39:382–387.
6. Australian Sexually Transmitted Infection and HIV Testing Guidelines for Asymptomatic Men Who Have Sex with Men 2014.  
[http://stipu.nsw.gov.au/wp-content/uploads/STIGMA\\_Testing\\_Guidelines\\_Final\\_v5.pdf](http://stipu.nsw.gov.au/wp-content/uploads/STIGMA_Testing_Guidelines_Final_v5.pdf). (accessed on March 5, 2015).
7. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010;59:1–110.
8. Hoover JB, Tao G, Heffelfinger JD. Monitoring HIV testing at visits to emergency departments in the United States: very-low rate of HIV testing. *J Acquir Immune Defic Syndr*.



- 2013;62:90-94.
9. Adam PC, de Wit JB, Toskin I, et al. Estimating levels of HIV testing, HIV prevention coverage, HIV knowledge, and condom use among men who have sex with men (MSM) in low-income and middle-income countries. *J Acquir Immune Defic Syndr*. 2009;52 Suppl 2:S143-151.
  10. Lister NA, Smith A, Fairley CK. Introduction of screening guidelines for men who have sex with men at an STD clinic, the Melbourne Sexual Health Centre, Australia. *Sex Health*. 2005;2:241-244.
  11. Ryder N, Bourne C, Rohrsheim R. Clinical audit: adherence to sexually transmitted infection screening guidelines for men who have sex with men. *Int J STD AIDS*. 2005;16:446-449.
  12. Bourne C, Knight V, Guy R, et al. Short message service reminder intervention doubles sexually transmitted infection/HIV re-testing rates among men who have sex with men. *Sex Transm Infect*. 2011;87:229-231.
  13. Cohen CE, Winston A, Asboe D, et al. Increasing detection of asymptomatic syphilis in HIV patients. *Sex Transm Infect*. 2005;81:217-219.
  14. Bissessor M, Fairley CK, Leslie D, et al. Frequent screening for syphilis as part of HIV monitoring increases the detection of early asymptomatic syphilis among HIV-positive homosexual men. *J Acquir Immune Defic Syndr*. 2010;55:211-216.
  15. Hotton AL, Gratzner B, Pohl D, et al. Factors associated with repeat syphilis testing at a large urban LGBT health clinic: Chicago, IL 2002-2008. *Sex Transm Dis*. 2010;38:205-209.
  16. Bissessor M, Fairley CK, Leslie D, et al. Use of a computer alert increases detection of early, asymptomatic syphilis among higher-risk men who have sex with men. *Clin Infect Dis*. 2011;53:57-58.
  17. Zou H, Fairley CK, Guy R, et al. Automated, computer generated reminders and increased detection of gonorrhoea, chlamydia and syphilis in men who have sex with men. *PLoS One*. 2013;8:e61972.
  18. Zou H, Wu Z, Yu J, et al. Sexual risk behaviors and HIV infection among men who have sex with men who use the internet in Beijing and Urumqi, China. *J Acquir Immune Defic Syndr*. 2010;53 Suppl 1:S81-87.
  19. Meng X, Zou H, Beck J, et al. Trends in HIV prevalence among men who have sex with men in China 2003-09: a systematic review and meta-analysis. *Sex Health*. 2013;10:211-219.
  20. China Daily. Gay stigma hindering HIV prevention in China. [http://m.chinadaily.com.cn/en/2015-12/01/content\\_22596045.htm](http://m.chinadaily.com.cn/en/2015-12/01/content_22596045.htm). (accessed on August 30, 2016).
  21. Lu F, Wang N, Wu Z, et al. Estimating the number of people at risk for and living with HIV in China in 2005: methods and results. *Sex Transm Infect*. 2006;82 Suppl 3:iii87-91.
  22. China Daily. Gay men hit hard by HIV/AIDS epidemic. [http://europe.chinadaily.com.cn/china/2015-11/20/content\\_22486775.htm](http://europe.chinadaily.com.cn/china/2015-11/20/content_22486775.htm). (accessed on August 30, 2016).
  23. Chow EP, Tucker JD, Wong FY, et al. Disparities and risks of sexually transmissible infections

- among men who have sex with men in China: a meta-analysis and data synthesis. *PLoS One*. 2014;9:e89959.
24. Zou H, Hu N, Xin Q, et al. HIV testing among men who have sex with men in China: a systematic review and meta-analysis. *AIDS Behav*. 2012;16:1717-1728.
25. Tang H, Mao Y, Shi CX, et al. Baseline CD4 cell counts of newly diagnosed HIV cases in China: 2006-2012. *PLoS One*. 2014;9:e96098.
26. Davis A, Best J, Luo J, et al. Risk behaviours, HIV/STI testing and HIV/STI prevalence between men who have sex with men and men who have sex with both men and women in China. *Int J STD AIDS*. 2015.
27. Lin L, Nehl EJ, Tran A, et al. Sexually transmitted infection testing practices among 'money boys' and general men who have sex with men in Shanghai, China: objective versus self-reported status. *Sex Health*. 2014;11:94-96.
28. Wuxi Municipal Government. Wuxi Economic and Social Development Statistical Report 2015. <http://www.wuxi.gov.cn/014006438/doc/2015/2/186988.shtml>. (accessed on March 17, 2015).
29. Guangzhou Economic and Social Development Statistics Bulletin 2015 (in Chinese). [http://www.gzstats.gov.cn/gzsq/201112/t20111229\\_27422.htm](http://www.gzstats.gov.cn/gzsq/201112/t20111229_27422.htm). (accessed on February 15, 2016).
30. Shenzhen Municipal Bureau of Statistics. Shenzhen economic data 2014. [http://www.szti.gov.cn/xxgk/tjsj/tjfx/201502/t20150228\\_2820587.htm](http://www.szti.gov.cn/xxgk/tjsj/tjfx/201502/t20150228_2820587.htm). (accessed on August 29, 2016).
31. Hornberger J, Holodniy M, Robertus K, et al. A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. *Med Decis Making*. 2007;27:789-821.
32. Kumar M, Birch S, Maturana A, et al. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India. *Health Policy*. 2006;77:233-243.
33. Owens DK, Nease RF, Jr, Harris RA. Cost-effectiveness of HIV screening in acute care settings. *Arch Intern Med*. 1996;156:394-404.
34. Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. *AIDS*. 2000;14:2159-2169.
35. Postma MJ, Beck EJ, Hankins CA, et al. Cost effectiveness of expanded antenatal HIV testing in London. *AIDS*. 2000;14:2383-2389.
36. Rozenbaum MH, Verweel G, Folkerts DK, et al. Cost-effectiveness estimates for antenatal HIV testing in the Netherlands. *Int J STD AIDS*. 2008;19:668-675.
37. Zaric GS, Bayoumi AM, Brandeau ML, et al. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. *J Acquir Immune Defic Syndr*. 2000;25:403-416.
38. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes (3rd edition). *Oxford University Press*. 2005.
39. Huang X, Lodi S, Fox Z, et al. Rate of CD4 decline and HIV-RNA change following HIV

seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. *J Acquir Immune Defic Syndr.* 2013;62:441-446.

40. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. *N Engl J Med.* 2005;352:586-595.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49




Figure 1. Flow chart of recruitment




Figure 2. Flowchart of study procedure



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	3-5
	2b	Specific objectives or hypotheses	5
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	N/A
Participants	4a	Eligibility criteria for participants	6-7
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	9-11
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	8
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	12-13
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	8
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	8
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	8
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	8
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	8

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	N/A
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	13-14
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	15-16
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	N/A
	13b	For each group, losses and exclusions after randomisation, together with reasons	N/A
Recruitment	14a	Dates defining the periods of recruitment and follow-up	7
	14b	Why the trial ended or was stopped	8
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	N/A
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	N/A
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	N/A
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	N/A
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	N/A
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	12
<b>Discussion</b>			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	19
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	18-19
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	19
<b>Other information</b>			
Registration	23	Registration number and name of trial registry	2
Protocol	24	Where the full trial protocol can be accessed, if available	N/A
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	20-21

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

# BMJ Open

## A randomized controlled trial to evaluate the impact of sexual-health-clinic-based automated text message reminders on the testing of HIV and other sexually transmitted infections in men who have sex with men in China: protocol for the T2T Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015787.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Mar-2017
Complete List of Authors:	Zou, Huachun; Sun Yat-sen University, School of Public Health Meng, Xiaojun; Wuxi Municipal Center for Disease Control and Prevention, Department of Infectious Disease Control Grulich, Andrew; The Kirby Institute, UNSW, Huang, Shuijie; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office Jia, Tianjian; Wuxi Municipal Center for Disease Control and Prevention, Department of Infectious Disease Control Zhang, Xuan; Wuxi Municipal Center for Disease Control and Prevention, Department of Infectious Disease Control Luo, Zhenzhou; Nanshan District Center for Chronic Disease Control and Prevention, STD Control Office Ding, Yi; Nanshan District Center for Chronic Disease Control and Prevention, STD Control Office Yang, Ligang; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office Huang, Jinmei; Guangdong Provincial Center for Skin Diseases and STDs Control, Chen, Weiyong; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office zheng, heping; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office Yang, Bin; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Health services research, Health policy, Sexual health
Keywords:	Text message service, Reminder, HIV, STI, Men who have sex with men, Sexual health clinic



SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-015787 on 10 July 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**A randomized controlled trial to evaluate the impact of  
sexual-health-clinic-based automated text message reminders on the  
testing of HIV and other sexually transmitted infections in men who  
have sex with men in China: protocol for the T2T Study**

Huachun Zou<sup>1,2#\*</sup>, Xiaojun Meng<sup>3#</sup>, Andrew Grulich<sup>2</sup>, Shujie Huang<sup>4,5</sup>, Tianjian Jia<sup>3</sup>,  
Xuan Zhang<sup>3</sup>, Zhenzhou Luo<sup>6</sup>, Yi Ding<sup>6</sup>, Ligang Yang<sup>4,5</sup>, Jinmei Han<sup>4,5</sup>, Weiyong  
Chen<sup>4,5</sup>, Heping Zheng<sup>4,5</sup> and Bin Yang<sup>4,5\*</sup>

1. School of Public Health, Sun Yat-sen University, Guangzhou, China
2. Kirby Institute, University of New South Wales, Sydney, Australia
3. Department of Infectious Disease Control, Wuxi Municipal Center for Disease Control and Prevention, Wuxi, China
4. Dermatology Hospital of Southern Medical University, Guangzhou, China
5. Guangdong Provincial Dermatology Hospital, Guangzhou, China
6. Nanshan District Center for Chronic Disease Control and Prevention, Shenzhen, China

# Huachun Zou and Xiaojun Meng contributed equally to this paper

**Corresponding authors**

Dr. Huachun Zou

School of Public Health, Sun Yat-sen University, Guangzhou, China

Email: zouhuachun@mail.sysu.edu.cn

Dr. Bin Yang

Dermatology Hospital of Southern Medical University, Guangzhou, China

Email: yangbin101@hotmail.com

## ABSTRACT

**Introduction:** The frequency of screening for HIV and other sexually transmitted infections (STIs) among men who have sex with men (MSM) is still low in China.

**Methods and analysis:** A sexual health clinic (SHC)-based randomized controlled trial will be conducted in Guangzhou, Wuxi and Shenzhen, China, enrolling 600 MSM. Eligibility will be judged by the pre-programed iPad-based questionnaire: 1) be  $\geq 18$  years of age, and 2) have had 2 or more male anal sex partners, or condomless anal sex with a casual male sex partner, or an STI history, in the past 6 months, and 3) provide a valid mobile number. Eligible men will be randomly allocated 1:1 to either Intervention Arm (with monthly text message reminding them to test for HIV/STIs) or Control Arm (without reminder). Men in both arms will complete a questionnaire onsite at enrollment and 12 months, and another questionnaire online at 6 months. Men in both arms will be tested for HIV, syphilis, anal gonorrhoea/chlamydia, and penile gonorrhoea/chlamydia at enrollment and 12 months. The primary outcome is the rate and frequency of HIV testing within the 12 months after enrolment. The secondary outcome is the rate of unprotected anal intercourse. An assessment of the cost-effectiveness of this intervention is also planned.

**Ethics and dissemination:** The study has been approved by the Ethical Review Committees of the University of New South Wales in Australia (HC16803), the Guangdong Provincial Center for Skin Disease and STI Control (GDDHLS-20160926) and Wuxi Center for Disease Control and Prevention (WXCDC2016009) in China. Study findings will be submitted to academic journals and disseminated to local health authorities.

**Trial registration number:** This study has been registered at the Chinese Clinical Trial Registry (<http://www.chictr.org.cn/enIndex.aspx>) and WHO International Clinical Trials Registry Platform (<http://www.who.int/ictrp/en/>), ID: ChiCTR-IPR-15006086.

## Keywords

Text message service; Reminder; HIV; STI; Men who have sex with men; Sexual

1  
2  
3 health clinic  
4  
5  
6

## 7 **ARTICLE SUMMARY**

8  
9

### 10 **Strengths and limitations of this study**

- 14 ■ No study has examined the role of sexual health clinic based automated short  
15 messaging services in the testing and detection of HIV/STIs in men who have sex  
16 with men (MSM) in China.
  - 17 ■ Findings from this study has the potential to help health authorities to develop new  
18 interventional strategies to control HIV/STIs among MSM in China.
  - 19 ■ This intervention, from judging eligibility to sending text message reminders, is  
20 wholly automated and requires limited human input, which can be easily replicated  
21 in other sexual health clinics in China and beyond.
  - 22 ■ Sexual behaviours and STI history during follow-up will be self-reported by  
23 participants, which may be subject to bias.
  - 24 ■ Loss to follow-up of participants is possible in this longitudinal study.
- 25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Men who have sex with men (MSM) in many countries are disproportionately affected by HIV and other sexually transmissible infections (STIs) such as gonorrhoea, chlamydia and syphilis<sup>1-4</sup>. More frequent screening for HIV and other STIs has the potential to improve detection of these largely asymptomatic infections, interrupting transmission and improving disease control<sup>5</sup>. Guidelines in a number of countries call for regular screening for HIV/STIs among MSM. For example, the US and Australian guidelines recommend that all MSM be screened for urethral and rectal chlamydia, pharyngeal and rectal gonorrhoea, syphilis and HIV at least once a year, with 3-6 monthly screening of MSM at higher-risk for HIV/STIs transmission<sup>6,7</sup>. However, available data suggest that the rate of screening for these infections among MSM is much lower than recommended in many countries<sup>8,9</sup>.

Significant increases in screening rates for gonorrhoea and chlamydia (Odds ratio (OR) range:1.4-1.9) have been demonstrated in observational studies using several different strategies: use of a computer alert on an electronic medical record<sup>10</sup>, the introduction of clinic guidelines on STI screening<sup>11</sup>, and short text messaging reminders for repeat STI screening<sup>12,13</sup>. Increases in syphilis testing (OR range: 2.3-21.4) were found using the following strategies: advocating regular serological screening for syphilis during routine HIV care<sup>14</sup>; including syphilis serology testing routinely with blood tests performed as part of HIV monitoring<sup>15</sup>; use of a computer alert on an electronic medical record<sup>16</sup>; and an electronic medical record system with a reminder to clinicians to enhance syphilis retesting following syphilis treatment<sup>17</sup>. A

1  
2  
3  
4 before-and-after study in Australia using existing clinical and behavioral data of  
5  
6 clients attending a major sexual health clinic (SHC) found that automated,  
7  
8 computer-generated text message service (SMS) 3-monthly reminders doubled the  
9  
10 testing rate for HIV, syphilis, gonorrhoea and chlamydia among MSM<sup>18</sup>. That study  
11  
12 also demonstrated an increased detection rate for syphilis, gonorrhoea and chlamydia,  
13  
14 but not for HIV<sup>18</sup>. Another before-and-after study in Australia found increased  
15  
16 HIV/STI re-testing rates among MSM as a result of 3-6 monthly SMS reminders at a  
17  
18 large SHC<sup>12</sup>. However until now there has been no randomized controlled trial to  
19  
20 confirm these effects.  
21  
22  
23  
24

25  
26 MSM in China are increasingly engaging in high risk sexual behaviors such as low  
27  
28 rate of condom use in anal sex, multiple concurrent partnerships and drug use during  
29  
30 sex<sup>19</sup>. The rates of HIV and STIs among this population are high and increasing. The  
31  
32 estimated HIV prevalence among MSM in China increased sharply over the past  
33  
34 decade: from 0.6% in 2003 to 8% in 2015<sup>20,21</sup>. Accordingly the proportion of MSM  
35  
36 among all people living with HIV/AIDS also climbed steadily: from 7% in 2005 to 25%  
37  
38 in 2015<sup>22,23</sup>. Many MSM in China were also infected with other STIs. A  
39  
40 meta-analysis found that the prevalence levels of STIs among MSM in China were 6%  
41  
42 for chlamydia, 2% for genital warts, 2% for gonorrhoea, 9% for hepatitis B, 1% for  
43  
44 hepatitis C, 66% for human papillomavirus and 11% for herpes simplex virus-2  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

24. However the testing rate for these infections was suboptimal. A systematic review  
found that less than 40% of MSM in China had tested for HIV in the past year<sup>25</sup>.  
Nearly half of MSM in China had a baseline CD4+ Cell count  $\leq 350$  per mm<sup>3</sup> at

1  
2  
3  
4 HIV diagnosis<sup>26</sup>. The rates of testing for other STIs were also low<sup>27,28</sup>. It is urgently  
5  
6  
7  
8  
9 needed to introduce an effective intervention that can increase testing and help  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

achieve timely diagnosis of HIV and other STIs among MSM in China.

Our study aims to use a randomized controlled trial to evaluate the role of SHC-based automated text message services in the testing and detection of HIV and other STIs among MSM in China.

## METHODS AND ANALYSIS

### Overview

The proposed protocol (dated December 8, 2016) was developed and facilitated by collaborations between experienced investigators from the Kirby Institute, the University of New South Wales (UNSW) in Sydney, Australia, Dermatology Hospital of Southern Medical University (DHSMU) in Guangzhou, China, Wuxi Center for Disease Control and Prevention (CDC) in Wuxi, China, Nanshan District Center for Chronic Disease Control and Prevention (CCDC) in Shenzhen, China, and Sun Yat-sen University in Guangzhou, China. The study will randomize 600 men who have sex with men (MSM) 1:1 into Intervention Group (with reminders) and Control Group (without reminders) and evaluate the role of SHC-based automated text message services in the testing and detection of HIV/STIs among MSM. A sample size of 300 MSM in each group will provide 90% power to detect a 15.0% (from 50% to 65%) difference in the proportion of HIV testing in the past 12 months between the two groups, considering 30% of loss-to-follow-up at 12 months.

## Objectives

The primary objective of this study is to determine the impact of SHC-based automated text message services on the testing and detection of HIV. The secondary objective is to determine the impact of SHC-based automated text message services on the change in sexual behaviors. The additional analysis is to evaluate the costs and incremental cost-effectiveness of the intervention.

## Study settings

This study will be based at the SHCs affiliated to DHSMU, Wuxi CDC and Shenzhen Nanshan CCDC. The population in Guangzhou, Wuxi and Shenzhen was around 13, 6 and 13 million, respectively, all with per capita gross domestic product (GDP) of over USD20,000 in 2014<sup>29-31</sup>. The three SHCs provide HIV/syphilis voluntary counseling and testing (VCT) and HIV/STI treatment services to over 25,000 clients annually, 10% of whom were estimated to be MSM (data not published). These three SHCs are equipped with microbiological diagnostic units and capable of timely testing and treating HIV and other STIs, including syphilis, gonorrhoea, chlamydia trachomatis and genital warts.

## Inclusion criteria

MSM attending the three clinics will be invited to join the study if they meet the following criteria: 1) anatomical men aged 18 years or older; 2) having over 2 male



1  
2  
3  
4 anal sex partners, or condomless anal sex with a casual male sex partner, or an STI  
5  
6 history including gonorrhea, syphilis, anogenital warts, genital herpes and chlamydia  
7  
8 trachomatis, in the past 6 months; 3) possessing a mobile phone; 4) willing to provide  
9  
10 informed consent for the collection of demographics, sexual behaviors and HIV/STI  
11  
12 testing experiences and biological samples to test for HIV/STIs; 5) residing in a study  
13  
14 city in the next 12 months or visiting a study city frequently enough to participate in  
15  
16 the study; 6) willing to register testing results if they test elsewhere during the study.  
17  
18  
19

#### 20 21 22 23 24 Exclusion criteria

25  
26 MSM who meets one or more criteria listed below will be excluded: 1) has psychiatric  
27  
28 illnesses; 2) unable to read or use the iPad questionnaire; 3) does not speak or read the  
29  
30 Chinese languages  
31  
32

#### 33 34 35 36 Study procedures

37  
38 Besides MSM attending the SHC affiliated to DHSMU, in Guangzhou we will also  
39  
40 work with local community clinics to refer MSM to attend the study. A study phone  
41  
42 number will be designated to this study. This randomized controlled trial will consist  
43  
44 of computer-assisted self-interview (CASI) and automated, computer-generated SMS  
45  
46 reminders among 600 MSM attending the SHCs. It will be conducted over 21-24  
47  
48 months: 3 months of logistic preparation, 3-6 months of recruitment, 12 months of  
49  
50 follow up and 3 months of report preparation. Detailed recruitment procedure is  
51  
52 described in Figure 1. Over a 3-6 months recruiting period, all male clients presenting  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 to the clinic will be given an information flyer by a receptionist who is not directly  
5  
6 involved in the study. The flyer will include basic information about the study,  
7  
8 including that it is a study for MSM. The receptionist will ask each male client to read  
9  
10 the flyer and to visit the study research assistant who sits at a nearby desk, if they are  
11  
12 interested in finding out more about the study. Those male clients who express interest  
13  
14 in participating will see the study research assistant, who will take them to a private  
15  
16 clinic room where an iPad questionnaire system is installed. The study research  
17  
18 assistant will explain what the study involves and go through the iPad-based full  
19  
20 Participant Information and Consent Form (PICF) with potential eligible participants.  
21  
22 Men will have time to read the PICF, to ask questions, and to decide if they will  
23  
24 participate in the study. Men will need to click the “Agree” button to consent before  
25  
26 completing an iPad-based questionnaire. The study research assistant will ask  
27  
28 consented participants to complete the iPad-based questionnaire on their own, in the  
29  
30 private room. They will be instructed that if they have any further questions, they  
31  
32 should ask the research assistant who will be at a desk, outside of the private room.  
33  
34 The questionnaire will collect information on sexual behaviours, HIV/STI testing  
35  
36 behaviours and diagnosis history and alcohol/tobacco/drug use. The pre-programmed  
37  
38 logic in the questionnaire will judge if a participant is actually eligible, based on  
39  
40 sexual behavior variables. Those who are not eligible will be thanked and released  
41  
42 back into the clinic waiting room for their routine clinical care. Eligible participants  
43  
44 will provide a valid mobile phone number and then be automatically randomised into  
45  
46 either intervention or control group, by the computer. They will then receive a text  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 message with a code as their Study ID. When they finish the PICF and questionnaire  
5  
6 participants will see the study research assistant who will guide them to see a doctor  
7  
8 for bio-specimen collection, followed by routine clinical care, if necessary. Eligible  
9  
10 MSM who opt out of the study will be recorded and asked about reasons to decline.  
11  
12

13  
14 Detailed study procedure is described in Figure 2. We acknowledge that directly  
15  
16 mentioning of sensitive words such as HIV and STIs in SMS reminders may lead to  
17  
18 the exposure of privacy of participants to others. As a result, we will avoid using these  
19  
20 sensitive words in actual SMS reminders. Instead, in actual reminders we will use  
21  
22 “*Little A*” to refer to “HIV”, “*Little B*” to refer to “STIs”, “*Health check*” to refer to  
23  
24 “HIV/STI testing”, “*Self health check*” to refer to “HIV self-testing at home”, and  
25  
26 “health kit” to refer to “condoms/lubes/MSM health manuals”. We will clarify this in  
27  
28 the PICF. All messages will include a withdrawal option.  
29  
30  
31  
32

33  
34 For MSM in the Intervention Group, upon enrolment, they will receive Message A:  
35  
36 “A gentle reminder: If you plan to have a health check again in the next 12 months,  
37  
38 welcome to our center. If you do it elsewhere (including self-health check) in the next  
39  
40 12 months, please register the results online at the following link: \*\*\*\*\*. Every time  
41  
42 you register we will compensate you with an electronic mobile phone credit of  
43  
44 CNY10 (USD1.5). If you change your mobile phone number in the next 12 months  
45  
46 please let us know.” When they register online, participants need to enter the mobile  
47  
48 phone number that was validated at enrolment and the initial of their surname to enter  
49  
50 the questionnaire. This is designed to avoid the exposure of sensitive questions to a  
51  
52 non participant. On the second day after enrolment, they will receive Message B: “A  
53  
54  
55  
56  
57  
58  
59  
60

gentle reminder: Little A and little B are spreading rapidly and it's hard to detect by yourself. Your best protection is a regular check-up (e.g. every 3 months). If you change your mobile phone number please let us know." Starting from day 30, they will receive Message C every 30 days: "A gentle reminder: If you have not had a health check in the past 3 months please do so as soon as possible. If you change your mobile phone number please let us know." On day 190, 10 days after they receive Message C on day 180, they will receive Message D, reminding them to complete an online survey about their sexual life and testing behaviors in the past 6 months: "A gentle reminder: please complete a survey at the following link at your earliest convenience: \*\*\*\*\*. We will compensate you with an electronic mobile phone credit of CNY50 (USD8). If you change your mobile phone number please let us know." On day 370, 10 days after they receive Message C on day 360, they will receive Message E, reminding them to complete an onsite survey about their sexual life and testing behaviours in the past 6 months: "A gentle reminder: please attend our center to complete the final survey. We will compensate you with an electronic mobile phone credit of CNY100 (USD16), together with a health kit. If you change your mobile phone number please let us know." At enrollment and 12 months men will be tested for HIV, syphilis, urethral and anal chlamydia and gonorrhoea, and examined for anogenital warts. CD4+ testing will be provided for men diagnosed with HIV. HIV/STIs will be treated as per relevant treatment guidelines in China. At 6 and 12 months men will also be asked questions about their experience of the intervention including the impact of the intervention on their everyday life, mental health, sexual

1  
2  
3  
4 health and general health (Figure 2).

5  
6 MSM in the Control Group will receive Message A upon enrolment, Message D on  
7  
8 day 190 and Message E on 370. They will not receive Messages B and C. They will  
9  
10 complete the same questionnaire as men in the intervention group do at enrolment, 6  
11  
12 months and 12 months and test for above-mentioned HIV/STIs at enrolment and 12  
13  
14 months. They will not be asked about their experience of the intervention.  
15  
16

17  
18 The 10 days' time gap between Messages C and D is planned to give men in both  
19  
20 groups enough time to attend a SHC upon receiving Message C. Besides men's  
21  
22 mobile phone number (compulsory) we will also try to collect other contact  
23  
24 information (optional), including email, QQ and WeChat ID (instant online messaging  
25  
26 applications frequently used in China). At 6 and 12 months, men will be contacted  
27  
28 with the additional contact information if they do not complete a designated survey  
29  
30 within 7 days after Messages D and E are sent. Men who register testing information  
31  
32 online or fill in an online questionnaire at 6 months will need to enter their mobile  
33  
34 number to access the actual questionnaire. This is designed in case another person  
35  
36 oversees the URL address from Message A. The process from commencing CASI to  
37  
38 the regular dispatch of the reminders will be entirely automated, requiring no human  
39  
40 input.  
41  
42  
43  
44  
45  
46  
47

48  
49 For men in both groups, at enrolment and 12 months, a study nurse will collect a  
50  
51 swab from the anal canal to test for anal gonorrhoea and chlamydia, and 5 ml of blood  
52  
53 to test to test for HIV and syphilis. Participants will self-collect a urine sample to test  
54  
55 for urethral gonorrhoea and chlamydia. A doctor will check ano-genital warts for each  
56  
57  
58  
59  
60

1  
2  
3  
4 participant. The HIV serologic status will be screened by ARCHITECT HIV Ag/Ab  
5  
6 Combo assay (Abbott Laboratories, Abbott Park, Illinois, USA). Positive samples will  
7  
8 be further screened by enzyme linked immunosorbent assay (ELISA) (Bio-Rad  
9  
10 Laboratories, CA, USA). Samples positive for ELISA will be confirmed by the  
11  
12 HIV-1/2 Western blot assay (HIV Blot 2.2 WB; Genelabs Diagnostics, Singapore).  
13  
14 Confirmed HIV cases will be tested for CD4+ T Cell count. Syphilis will be screened  
15  
16 by the toluidine red unheated serum test (TRUST) (RSbio, Shanghai, China) and  
17  
18 samples positive for TRUST will be confirmed by treponema pallidum particle assay  
19  
20 (TPPA) (Fuji ReBio, Tokyo, Japan). Anal and urethral gonorrhea and chlamydia will  
21  
22 be tested using polymerase chain reaction (PCR) (Roche Diagnostics, Shanghai,  
23  
24 China). Ano-genital warts will be checked by a doctor with the assistance of acetic  
25  
26 acid test.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

### 37 **Incentives and retention**

38  
39 Study participants will receive health education materials, condoms and lubricant  
40  
41 upon completion of the CASI questionnaire at enrolment and 12 months. Participants  
42  
43 will receive an electronic mobile phone credit of CNY50 (USD8), CNY50 (USD8)  
44  
45 and CNY100 (USD16), upon completion of the surveys at enrolment, 6 months and  
46  
47 12 months. Participants who test elsewhere will receive an additional electronic  
48  
49 mobile phone credit CNY 10 (USD 1.5) each time they register testing results online.  
50  
51  
52  
53  
54  
55

### 56 **Statistical methods**

### *Power/sample size*

We used the following formula to calculate sample size:

$$n = \frac{(Z_{\alpha} \sqrt{2pq} + Z_{\beta} \sqrt{p_0q_0 + p_1q_1})^2}{(p_1 - p_0)^2}$$

In this formula,  $Z_{\alpha}$  and  $Z_{\beta}$  represent the  $Z$  boundaries under the standard normal distribution;  $p_1$  and  $p_0$  represents proportion of a parameter in the intervention group and control group, respectively;  $p$  equals to the average of  $p_1$  and  $p_0$ ;  $q=1-p$ . We used 2 parameters in the calculation of sample size: (a) proportion of men who have HIV testing during the 12 months after baseline; (b) proportion of men who have condomless anal sex during the 12 months after baseline. We assumed a two-sided hypothesis test with a 5% significance level ( $Z_{\alpha/2}=1.96$ ), a desired power of 90% ( $Z_{\beta}=1.28$ ), and that both groups will have the same number of observations.

Using parameter (a), the rate of HIV testing in the past 12 months among MSM in Wuxi in 2014 was 50% ( $p_0$ ), and this figure was expected to increase to 65% ( $p_1$ ) according to a before-and-after study in Australia<sup>18</sup>. This resulted in a sample size of 225 in each group. Khosropour et al., retained around 70% of MSM for 12 months using bimonthly follow-up surveys through text messages<sup>30</sup>. We will adopt a number of strategies to minimize the loss-to-follow-up rate: educating investigators about the culture in MSM community and develop rapport with participants; verifying mobile number at enrolment; contacting participants on days 190 and 370 using various messaging softwares/apps such as WeChat, QQ, email, etc; and reasonable incentives. Considering a loss-to-follow-up rate of 30%, a sample size of 300 MSM in each group will be needed.

### *Analysis plan*

Analyses will be performed using STATA 13.0 (College Station, TX, USA) statistical analysis software. All effects will be estimated with a 95% confidence intervals and p-values from the corresponding hypothesis tests. Statistical significance will be taken as two sided p-value less than 0.05, with no adjustment for multiple comparisons. Characteristics of groups will be summarized at baseline and across study arms. Mean duration of study follow-up will be compared by group.

Primary analysis will compare randomized groups of MSM using an intention to treat approach. Initial analyses will be simple, unadjusted comparisons of randomised groups. If there appears to be any important imbalances between randomised groups in terms of baseline covariates, adjusted analyses will also be performed.

For the comparison of HIV/STIs testing and detection between the two groups at the end of the study: 1) we will use Cox proportional hazard models with Kaplan Meier plots and log-rank test to explore the cumulative rate of reported HIV/STIs testing and detection during the previous 12 months, comparing the two groups. Number of testing and detection of each infection will also be compared. 2) we will use Chi-square test to compare the proportion of reported HIV/STIs testing and detection during the previous 12 months before intervention with that during the 12 months after intervention, within Intervention Group. Number of testing and detection of each infection will also be compared.



1  
2  
3  
4 For the comparison of behavioural change between the two groups at the end of  
5  
6 the study: 1) we will use Chi-square test to compare the proportion of reported  
7  
8 condomless anal sex during the previous 12 months between the two groups. 2) we  
9  
10 will use rank sum test to compare the number of reported anal sex partners during  
11  
12 the previous 12 months between the two groups. 3) we will use Chi-square test to  
13  
14 compare the proportion of reported condomless anal sex during the previous 12  
15  
16 months before intervention with that during the 12 months after intervention, within  
17  
18 Intervention Group. 4) we will use rank sum test to compare the number of reported  
19  
20 anal sex partners during the previous 12 months before intervention with that during  
21  
22 the 12 months after intervention, within Intervention Group.  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Additional analyses**

#### 32 *Cost and cost-effectiveness evaluation*

33  
34 Although some studies have assessed the cost-effectiveness of HIV testing methods  
35  
36 among high-risk populations in some regions <sup>32-38</sup>, whether the intervention in this  
37  
38 study is cost-effective is unclear. As a result, the costs and incremental  
39  
40 cost-effectiveness of the intervention compared to control will be evaluated, using  
41  
42 standard methods of cost-effectiveness analysis <sup>39</sup>. Our analysis will include the  
43  
44 costs of the self-registration and SMS reminding system development and  
45  
46 maintenance, HIV/STI testing and counseling, follow-up, and treatment. All costs  
47  
48 will be measured from a societal perspective, and inflated to 2015 Chinese Yuan at a  
49  
50 discounting rate of 3% annually.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Cost-Effectiveness analysis*

Based on incremental cost-effectiveness analysis, we will calculate the incremental cost for one additional newly identified HIV/STI case, and one additional early HIV case, using the following formula<sup>39</sup>:

$$ICER_{ij} = (C_i - C_j) / (E_i - E_j)$$

### *Markov model based Cost-Utility analysis*

We will develop a decision model to reflect when successful HIV/STI detection, follow-up, and treatment occur for a cohort of MSM with/without intervention, and then a Markov model estimating the lifecycle of MSM from entering the cohort until death, to examine the incremental cost-utility of intervention. Effectiveness is measured as quality adjusted life-years (QALYs) gained. We assume that QALYs accrues by early initiation of antiretroviral therapy (ART) following early HIV detection. According to the actual situation in China, the natural history of HIV/AIDS is categorized as the following stages: asymptomatic HIV, symptomatic HIV, AIDS and death. Health states summarizes current status based on CD4+ T cell count, quality of life, ART usage and resource use. ART and CD4+ T cell count combined determines the transition probabilities and mortality rates<sup>40 41</sup>. The model will assess HIV status, stage transfer and its consequences among MSM with incident HIV infection on an annual basis. All the parameters used in this model will be compiled from a variety of sources, including literature review, ongoing cohort

1  
2  
3 studies and investigations, surveillance data or unpublished data from Wuxi and  
4  
5  
6 other parts of China.  
7

8  
9 In this study, we assume that: (1) stage transition in the Markov model happens  
10  
11 once a year, (2) once an HIV infected man receives ART, he will complete the entire  
12  
13 treatment procedure. To account for assumptions and uncertainties of this model, we  
14  
15 will perform one-way sensitivity analyses on all model parameters. For all the  
16  
17 probability variables, our ranges for sensitivity analyses represent our judgment of  
18  
19 the variation on the basis of both the literature and discussion with experts.  
20  
21  
22  
23

### 24 25 **Sample/data storage**

26  
27 All electronic questionnaires, consent forms will be stored in a password-protected  
28  
29 computer at the information center at DHSMU as per its common practice. The data  
30  
31 will be stored in a format that is identifiable. This is designed to match data with  
32  
33 individual participants in follow-up visits in this study. However, only the custodian  
34  
35 will have access to the original data. All identifying variables, including name (a  
36  
37 pseudonym is ok), initial of participant's surname, mobile phone number and date of  
38  
39 birth, will be de-identified before data are transferred to a data analyst in this study.  
40  
41  
42 The custodian will ensure that data is stored and managed appropriately and  
43  
44 according to the relevant privacy laws. The data custodian will only share data with  
45  
46 researchers who are conducting HIV/STI testing related epidemiologic studies and  
47  
48 only once these projects have received separate ethics approval from a Human  
49  
50 Research Ethics Committee. All identifying variables, including name (a pseudonym  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 is ok), initial of participant's surname, mobile phone number and date of birth, will  
5  
6 be de-identified before data sharing. Bio-specimen collected at a given site will be  
7  
8 stored at the corresponding participatory institution.  
9

## 10 11 12 13 14 **ETHICS AND DISSEMINATION**

15  
16 The study has been approved by the Ethical Review Committees of the University of  
17  
18 New South Wales in Australia (HC16803), the Dermatology Hospital of Southern  
19  
20 Medical University (GDDHLS-20160926) and Wuxi Center for Disease Control and  
21  
22 Prevention (WXCDC2016009) in China. We anticipate that the benefits of study  
23  
24 participation will outweigh any risks, including loss of confidentiality and privacy of  
25  
26 clinical information. Participants will benefit from frequent testing and early  
27  
28 diagnosis of HIV/STIs and timely treatment if positive. The findings of the study  
29  
30 will be disseminated to local and national government in China as well as the wider  
31  
32 academic audience and public health organizations through peer-reviewed  
33  
34 publications and international conferences.  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **DISCUSSION**

45  
46 This study protocol describes a randomized controlled trial designed to increase the  
47  
48 testing and detection of HIV and other STIs among Chinese MSM through  
49  
50 computer-assisted self-interview and automated computer generated reminders.  
51  
52 Firstly, we seek to develop a platform requiring limited investment and human  
53  
54 power that could be easily replicated and deployed in other SHCs in China and  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 beyond. As such, one of the challenges in designing the intervention was the  
5  
6 acceptance of it among target population-MSM in China-a population that has long  
7  
8 been marginalized and discriminated against. Fortunately in our unpublished  
9  
10 pre-trial study, almost 80% of MSM in the community were willing to take such an  
11  
12 intervention. It is estimated that this rate would be even higher among MSM  
13  
14 attending SHCs. Other key challenges to this study include the need to sustain the  
15  
16 motivation of clinic staff to participate in the study while addressing the multiple  
17  
18 competing health priorities. Secondly, we will be able to understand MSM with what  
19  
20 characteristics are more likely to take this intervention and barriers that prevent other  
21  
22 MSM from taking this intervention. This will help develop an intervention that is  
23  
24 contextualized and tailored to the characteristics of MSM. Thirdly, if successful, this  
25  
26 intervention with high potential cost-effectiveness will contribute to the compilation  
27  
28 of the fabric of quality SHCs and health providers that will eventually be readily  
29  
30 available to MSM at their finger tips. This will greatly encourage and facilitate them  
31  
32 to test for HIV/STIs on a more frequent basis. Lastly, results from this study may  
33  
34 facilitate the development of proactive interventions strategies targeting other at-risk  
35  
36 populations, such as female sex workers and their clients, and drug users, etc. to  
37  
38 increase the testing and detection of HIV and other STIs and hence prevent the  
39  
40 transmission of these infections.  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 This intervention has its limitations: Firstly, the 12-months research period is a  
52  
53 long commitment for MSM as many of them are quite mobile. The retention rate  
54  
55 could be compromised by 12 months. To tackle this problem we will verify  
56  
57  
58  
59  
60

1  
2  
3  
4 participants' mobile phone number at enrolment and remind them to update their  
5  
6 mobile number every 30 days. Additionally we will also use other contact  
7  
8 information reported by participants to achieve the highest possible retention rate.  
9  
10  
11 Secondly, men could forget to register testing experience from other venues. To  
12  
13 tackle this problem, we will remind them to do this in Message A at enrolment.  
14  
15 Because a similar reminder during the study would potentially bring about  
16  
17 contamination to the intervention, we will not send further reminders. Thirdly, as  
18  
19 this intervention will be conducted in metropolitan cities, the results may not apply  
20  
21 to that in other settings.  
22  
23  
24

25  
26 In summary the knowledge gained from this study may be used to design similar  
27  
28 protocols with a higher number of participants and appropriate intervention  
29  
30 strategies to reduce the burden of HIV and other STIs among MSM, a population  
31  
32 who is heavily burdened by these infections. Additionally, if the results are positive,  
33  
34 we will scale up this practice in more SHCs across China.  
35  
36  
37  
38  
39  
40

## 41 **Acknowledgments**

42  
43 We thank Dr. Qianqian Xin from the Capital Institute of Pediatric in Beijing, Dr. Gang  
44  
45 Zeng from Alere Inc Beijing and Dr. Jinghua Li from Sun Yat-sen University for their  
46  
47 comments to the protocol.  
48  
49  
50

## 51 **Authors' contribution**

52  
53 Huachun Zou and Xiaojun Meng initiated this research plan and designed this  
54  
55 protocol with Bin Yang and Andrew Grulich consulting on ethics and feasibility of  
56  
57  
58  
59  
60

1  
2  
3 the research. Zhenzhou Luo, Tianjian Jia, Xuan Zhang, Yi Ding and Ligang Yang  
4 provided expertise on recruitment and sample collection and will supervise these  
5 aspects at the three study clinics. Jinmei Huang, Shujie Huang and Heping Zheng  
6 provided expertise on sample testing and storage. Weiyong Chen helped with the  
7 design of questionnaire and recruitment methods.  
8  
9  
10  
11  
12  
13

## 14 15 16 **Funding**

17 This work was supported by a grant from Australian National Health and Medical  
18 Research Commission (NHMRC) Early Career Fellowship (APP1092621) and  
19 research grants from Guangdong Provincial Center for Skin Disease and STI Control  
20 (YCS201669), Wuxi municipal health and Family Planning Commission  
21 (MS201613), Wuxi Municipal Science and Technology Bureau (CSZ0N1512) and  
22 Nanshan District Center for Chronic Disease Control and Prevention. The funding  
23 bodies other than NHMRC participated in study design, data collection and analysis,  
24 preparation of the manuscript, and the decision to publish.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 37 **Competing interests**

38 All authors declare no competing interests.  
39

## 40 41 **References**

- 42 1. Hu J, Gu X, Tao X, et al. Prevalence and Trends of HIV, Syphilis, and HCV in Migrant and  
43 Resident Men Who Have Sex with Men in Shandong, China: Results from a Serial  
44 Cross-Sectional Study. *PLoS One*. 2017;12:e0170443.
- 45 2. Hernandez I, Johnson A, Reina-Ortiz M, et al. Syphilis and HIV/Syphilis Co-infection Among  
46 Men Who Have Sex With Men (MSM) in Ecuador. *Am J Mens Health*. 2016.
- 47 3. Vodstrcil LA, Fairley CK, Fehler G, et al. Trends in Chlamydia and Gonorrhoea Positivity among  
48 Heterosexual Men and Men who have sex with Men attending a large urban sexual health  
49 service in Australia, 2002-2009. *BMC Infect Dis*. 2011;11:158.
- 50 4. Keshinro B, Crowell TA, Nowak RG, et al. High prevalence of HIV, chlamydia and gonorrhoea  
51 among men who have sex with men and transgender women attending trusted community  
52 centres in Abuja and Lagos, Nigeria. *J Int AIDS Soc*. 2016;19:21270.
- 53 5. Zou H, Fairley CK, Guy R, et al. The efficacy of clinic-based interventions aimed at increasing  
54 screening for bacterial sexually transmitted infections among men who have sex with men:  
55  
56  
57  
58  
59  
60

- a systematic review. *Sex Transm Dis*. 2012;39:382-387.
6. Australian Sexually Transmitted Infection and HIV Testing Guidelines for Asymptomatic Men Who Have Sex with Men 2014. Available at: [http://stipu.nsw.gov.au/wp-content/uploads/STIGMA\\_Testing\\_Guidelines\\_Final\\_v5.pdf](http://stipu.nsw.gov.au/wp-content/uploads/STIGMA_Testing_Guidelines_Final_v5.pdf). Verified on March 5, 2015.
  7. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010;59:1-110.
  8. Witzel TC, Melendez-Torres GJ, Hickson F, et al. HIV testing history and preferences for future tests among gay men, bisexual men and other MSM in England: results from a cross-sectional study. *BMJ Open*. 2016;6:e011372.
  9. Marcus U, Gassowski M, Drewes J. HIV risk perception and testing behaviours among men having sex with men (MSM) reporting potential transmission risks in the previous 12 months from a large online sample of MSM living in Germany. *BMC Public Health*. 2016;16:1111.
  10. Lister NA, Smith A, Fairley CK. Introduction of screening guidelines for men who have sex with men at an STD clinic, the Melbourne Sexual Health Centre, Australia. *Sex Health*. 2005;2:241-244.
  11. Ryder N, Bourne C, Rohrsheim R. Clinical audit: adherence to sexually transmitted infection screening guidelines for men who have sex with men. *Int J STD AIDS*. 2005;16:446-449.
  12. Bourne C, Knight V, Guy R, et al. Short message service reminder intervention doubles sexually transmitted infection/HIV re-testing rates among men who have sex with men. *Sex Transm Infect*. 2011;87:229-231.
  13. Nyatsanza F, McSorley J, Murphy S, et al. 'It's all in the message': the utility of personalised short message service (SMS) texts to remind patients at higher risk of STIs and HIV to reattend for testing-a repeat before and after study. *Sex Transm Infect*. 2016;92:393-395.
  14. Cohen CE, Winston A, Asboe D, et al. Increasing detection of asymptomatic syphilis in HIV patients. *Sex Transm Infect*. 2005;81:217-219.
  15. Bissessor M, Fairley CK, Leslie D, et al. Frequent screening for syphilis as part of HIV monitoring increases the detection of early asymptomatic syphilis among HIV-positive homosexual men. *J Acquir Immune Defic Syndr*. 2010;55:211-216.
  16. Hotton AL, Gratzner B, Pohl D, et al. Factors associated with repeat syphilis testing at a large urban LGBT health clinic: Chicago, IL 2002-2008. *Sex Transm Dis*. 2010;38:205-209.
  17. Bissessor M, Fairley CK, Leslie D, et al. Use of a computer alert increases detection of early, asymptomatic syphilis among higher-risk men who have sex with men. *Clin Infect Dis*. 2011;53:57-58.
  18. Zou H, Fairley CK, Guy R, et al. Automated, computer generated reminders and increased detection of gonorrhoea, chlamydia and syphilis in men who have sex with men. *PLoS One*. 2013;8:e61972.
  19. Zou H, Wu Z, Yu J, et al. Sexual risk behaviors and HIV infection among men who have sex with men who use the internet in Beijing and Urumqi, China. *J Acquir Immune Defic Syndr*. 2010;53 Suppl 1:S81-87.
  20. Meng X, Zou H, Beck J, et al. Trends in HIV prevalence among men who have sex with men in China 2003-09: a systematic review and meta-analysis. *Sex Health*. 2013;10:211-219.
  21. China Daily. Gay stigma hindering HIV prevention in China. Available at:



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- [http://m.chinadaily.com.cn/en/2015-12/01/content\\_22596045.htm](http://m.chinadaily.com.cn/en/2015-12/01/content_22596045.htm). Verified on: August 30, 2016.
22. Lu F, Wang N, Wu Z, et al. Estimating the number of people at risk for and living with HIV in China in 2005: methods and results. *Sex Transm Infect.* 2006;82 Suppl 3:iii87-91.
23. China Daily. Gay men hit hard by HIV/AIDS epidemic. Available at: [http://europe.chinadaily.com.cn/china/2015-11/20/content\\_22486775.htm](http://europe.chinadaily.com.cn/china/2015-11/20/content_22486775.htm). Verified on: August 30, 2016.
24. Chow EP, Tucker JD, Wong FY, et al. Disparities and risks of sexually transmissible infections among men who have sex with men in China: a meta-analysis and data synthesis. *PLoS One.* 2014;9:e89959.
25. Zou H, Hu N, Xin Q, et al. HIV testing among men who have sex with men in China: a systematic review and meta-analysis. *AIDS Behav.* 2012;16:1717-1728.
26. Tang H, Mao Y, Shi CX, et al. Baseline CD4 cell counts of newly diagnosed HIV cases in China: 2006-2012. *PLoS One.* 2014;9:e96098.
27. Davis A, Best J, Luo J, et al. Risk behaviours, HIV/STI testing and HIV/STI prevalence between men who have sex with men and men who have sex with both men and women in China. *Int J STD AIDS.* 2015.
28. Lin L, Nehl EJ, Tran A, et al. Sexually transmitted infection testing practices among 'money boys' and general men who have sex with men in Shanghai, China: objective versus self-reported status. *Sex Health.* 2014;11:94-96.
29. Wuxi Municipal Government. Wuxi Economic and Social Development Statistical Report 2015. Available at: <http://www.wuxi.gov.cn/014006438/doc/2015/2/186988.shtml>. Verified: March 17, 2015.
30. Guangzhou Economic and Social Development Statistics Bulletin 2015 (in Chinese). Available at: [http://www.gzstats.gov.cn/gzsq/201112/t20111229\\_27422.htm](http://www.gzstats.gov.cn/gzsq/201112/t20111229_27422.htm). Verified on: February 15, 2016.
31. Shenzhen Municipal Bureau of Statistics. Shenzhen economic data 2014. Available at: [http://www.szjt.gov.cn/xxgk/tjsj/tjfx/201502/t20150228\\_2820587.htm](http://www.szjt.gov.cn/xxgk/tjsj/tjfx/201502/t20150228_2820587.htm). Verified on: August 29, 2016.
32. Hornberger J, Holodniy M, Robertus K, et al. A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. *Med Decis Making.* 2007;27:789-821.
33. Kumar M, Birch S, Maturana A, et al. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India. *Health Policy.* 2006;77:233-243.
34. Owens DK, Nease RF, Jr., Harris RA. Cost-effectiveness of HIV screening in acute care settings. *Arch Intern Med.* 1996;156:394-404.
35. Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. *AIDS.* 2000;14:2159-2169.
36. Postma MJ, Beck EJ, Hankins CA, et al. Cost effectiveness of expanded antenatal HIV testing in London. *AIDS.* 2000;14:2383-2389.
37. Rozenbaum MH, Verweel G, Folkerts DK, et al. Cost-effectiveness estimates for antenatal HIV testing in the Netherlands. *Int J STD AIDS.* 2008;19:668-675.
38. Zaric GS, Bayoumi AM, Brandeau ML, et al. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. *J Acquir Immune Defic Syndr.* 2000;25:403-416.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
39. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes (3rd edition). *Oxford University Press*. 2005.
40. Huang X, Lodi S, Fox Z, et al. Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. *J Acquir Immune Defic Syndr*. 2013;62:441-446.
41. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. *N Engl J Med*. 2005;352:586-595.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Flow chart of recruitment

Flow chart of recruitment

83x40mm (300 x 300 DPI)




Figure 2. Flowchart of study procedure

Flowchart of study procedure

109x68mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	ItemNo	Description	Reported on page No
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	<u>1</u>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	<u>2</u>
	2b	All items from the World Health Organization Trial Registration Data Set	<u>2</u>
Protocol version	3	Date and version identifier	<u>6</u>
Funding	4	Sources and types of financial, material, and other support	<u>21</u>
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	<u>21</u>
	5b	Name and contact information for the trial sponsor	<u>21</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>21</u>

1			
2			
3			
4			
5			
6		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
7			<u>N/A</u>
8			
9			
10	<b>Introduction</b>		
11			
12	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
13			<u>4-6</u>
14			
15			
16		6b	Explanation for choice of comparators
17			<u>4-6</u>
18	Objectives	7	Specific objectives or hypotheses
19			<u>7</u>
20	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
21			<u>6</u>
22			
23			
24			
25			
26	<b>Methods: Participants, interventions, and outcomes</b>		
27			
28	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
29			<u>7</u>
30			
31			
32	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
33			<u>7-8</u>
34			
35			
36	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
37			<u>10-11</u>
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>N/A</u>
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	<u>13</u>
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>N/A</u>
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>14-17</u>
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	<u>8</u>
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<u>13-14</u>
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>8</u>

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

1				
2				
3				
4				
5	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random	<u>9</u>
6	generation		numbers), and list of any factors for stratification. To reduce predictability of a random	
7			sequence, details of any planned restriction (eg, blocking) should be provided in a	
8			separate document that is unavailable to those who enrol participants or assign	
9			interventions	
10				
11				
12	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially	<u>9</u>
13	concealment		numbered, opaque, sealed envelopes), describing any steps to conceal the sequence	
14	mechanism		until interventions are assigned	
15				
16	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will	<u>9</u>
17			assign participants to interventions	
18				
19	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care	<u>9</u>
20			providers, outcome assessors, data analysts), and how	
21				
22		17b	If blinded, circumstances under which unblinding is permissible, and procedure for	<u>9</u>
23			revealing a participant's allocated intervention during the trial	
24				
25				
26	<b>Methods: Data collection, management, and analysis</b>			
27				
28	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including	<u>17-18</u>
29	methods		any related processes to promote data quality (eg, duplicate measurements, training of	
30			assessors) and a description of study instruments (eg, questionnaires, laboratory tests)	
31			along with their reliability and validity, if known. Reference to where data collection	
32			forms can be found, if not in the protocol	
33				
34		18b	Plans to promote participant retention and complete follow-up, including list of any	<u>17-18</u>
35			outcome data to be collected for participants who discontinue or deviate from	
36			intervention protocols	
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>17-18</u>
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>15</u>
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>16-17</u>
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>15</u>
<b>Methods: Monitoring</b>			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>17-18</u>
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>18</u>
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>N/A</u>
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>N/A</u>
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>18</u>

1			
2			
3			
4			
5	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
6			<u>19</u>
7			
8			
9			
10	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
11			<u>8-9</u>
12			
13		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
14			<u>27</u>
15			
16	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
17			<u>17-18</u>
18			
19			
20	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site
21			<u>21</u>
22			
23	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
24			<u>18</u>
25			
26	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
27			<u>N/A</u>
28			
29			
30	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
31			<u>18</u>
32			
33			
34			
35		31b	Authorship eligibility guidelines and any intended use of professional writers
36			<u>N/A</u>
37		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code
38			<u>18</u>
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

**Appendices**

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>27</u>
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	<u>12</u>

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

For peer review only

## Sample patient information and consent form

### 1. What is the research study about?

Over 7% of men who have sex with men (MSM) in China have been infected with HIV, with over 10% infected with syphilis and over 30% infected with gonorrhoea, condyloma and other sexually transmitted infections (STIs). You are cordially invited to participate in a study about HIV/STI testing, jointly conducted by Guangdong Provincial Center for Skin Disease and STI Control, Wuxi Municipal Center for Disease Control and Prevention, Shenzhen Nanshan Center for Chronic Disease Control and Prevention, Sun Yat-sen University and the University of New South Wales. This study aims to understand if automated short message service (SMS) reminders can lead to frequent testing and early diagnosis/treatment among MSM. Your participation will help us to improve HIV prevention strategy for the MSM community.

If you are eligible and willing to participate in this study, you will need to provide a valid phone number that will be verified by a code sent to you via SMS. Participants will be randomly allocated into two groups: one group will receive a testing reminder via SMS every 30 days, while the other group will not receive any reminder.

### 2. Inclusion/Exclusion Criteria

Before you decide to participate in this research project, we need to ensure that it is ok for you to take part. If you have ever had a male sex partner you may be eligible to participate in the study. Your eligibility will be judged by the logic pre-programmed in the questionnaire that you will see, if you agree to participate.

### 3. Do I have to take part in this research study?

Participation in any research project is voluntary. If you do not want to take part, you do not have to. If you decide to take part and later change your mind, you are free to withdraw from the project at any stage.

If you decide you want to take part in the research study, you will be asked to:

- Read the information carefully (ask questions if necessary);
- If you would like to participate, sign the consent form;.

### 4. What does participation in this research require, and are there any risks involved?

If you are eligible and decide to take part in the research study, you will be randomly assigned to either **Group A** (receive monthly reminders to remind you to test for HIV/STIs) or **Group B** (no monthly reminders). We will ask you to complete the following tasks:

#### [Completion of Questionnaires]

Today, the research team will ask you to complete an iPad-based questionnaire. This questionnaire will ask you questions about your socio-demographic characteristics, sexual behaviours, HIV/STI testing and diagnosis experiences, attitudes towards HIV pre-exposure prophylaxis, blood donation experiences, and geo-social networking app use experiences. It should take approximately 15 minutes to complete.

At 6 months, the research team will ask you to complete another online questionnaire. This questionnaire will ask you questions about your experiences in the past 6 months, including sexual behaviours, HIV/STI testing and diagnosis experiences, blood donation experiences, and geo-social networking app use experiences. It should take approximately 10 minutes to complete.

At 12 months, the research team will ask you to come back to this site to complete another iPad-based questionnaire. This questionnaire will ask you questions about your experiences in the past 6 months, including sexual behaviours, HIV/STI testing and diagnosis experiences, blood donation experiences, and geo-social networking app use experiences. It should take approximately 10 minutes to complete.

If you are assigned to **Group A**, at 6 and 12 months you will also be asked questions about your experience of the monthly reminders including the impact of the intervention on

your everyday life, mental health, sexual health and general health. You will not be asked these questions if you are assigned to **Group B**.

We don't expect these questionnaires to cause any harm or discomfort, however if you experience feelings of distress as a result of participation in this study you can let the research team know and they will provide you with assistance. Alternatively lists of services are provided in the contact details below to assist you if necessary.

#### [Collection of biospecimen]

Today, a study nurse will collect the following biospecimen from you: an anal swab, a urine sample and 10ml of blood sample. A doctor will also check ano-genital warts for you. It should take approximately 20 minutes to complete.

At 12 months, in the last survey, the research team will ask you to come back to this site. Besides a questionnaire, a study nurse will collect the following biospecimen from you: an anal swab, a urine sample and 10ml of blood sample. A doctor will also check ano-genital warts for you. It should take approximately 20 minutes to complete.

#### [HIV/STI testing]

Today and at 12 months when you come to this site for the last onsite survey, you will be tested for HIV, syphilis, urethral and anal chlamydia and gonorrhoea, and examined for anogenital warts. CD4+ testing will be provided for you if you are diagnosed with HIV. HIV/STIs will be treated as per relevant treatment guidelines in China.

#### [SMS reminders]

We acknowledge that directly mentioning of sensitive words such as HIV and STIs in SMS reminders may lead to the exposure of privacy of participants to others. As a result, we will avoid using these sensitive words in actual SMS reminders. Instead, in actual reminders we will use "**Little A**" to refer to "HIV", "**Little B**" to refer to "STIs", "**Health check-up**" to refer to "HIV/STI testing", "**Self check-up**" to refer to "HIV self-testing at home" and "health kit" to refer to "condoms/lubes/health manuals".

If you are in **Group A**, after completion of the iPad-based questionnaire you will receive **Message A**: "A gentle reminder: If you plan to have a health check again in the next 12 months, welcome to our center. If you do it elsewhere (including self-health check) in the next 12 months, please register the results online at the following link: \*\*\*\*\*. Every time you register we will compensate you with an electronic mobile phone credit of CNY10 (USD1.5). If you change your mobile phone number in the next 12 months please let us know." Tomorrow, you will receive **Message B**: "A gentle reminder: **Little A** and **Little B** are spreading rapidly and it's hard to detect by yourself. Your best protection is a regular check-up (e.g. every 3 months). If you change your mobile phone number please let us know." Starting from day 30, you will receive **Message C** every 30 days: "A gentle reminder: If you have not had a health check in the past 3 months please do so as soon as possible. If you change your mobile phone number please let us know." On day 190, you will receive **Message D**: "A gentle reminder: please complete a survey at the following link at your earliest convenience: \*\*\*\*\*. We will compensate you with an electronic mobile phone credit of CNY50 (USD8). If you change your mobile phone number please let us know." On day 370, you will receive **Message E**, reminding you to complete an onsite survey about your sexual life and testing behaviours in the past 6 months: "A gentle reminder: please attend our center to complete the final survey. We will compensate you with an electronic mobile phone credit of CNY100 (USD16), together with a health kit. If you change your mobile phone number please let us know."

If you assigned to **Group B**, you will receive **Message A** today, **Message D** on day 190 and **Message E** on 370. You will not receive **Messages B** and **C**.

You are free to withdraw from the SMS reminders by calling our study phone number at any time. You are free to withdraw from the research at any time. If you withdraw from the research we will destroy any information that has already been collected.

1  
2  
3  
4  
5  
6  
7  
8  
9

#### 5. What are the possible benefits to participation?

We hope to use information we get from this research study to benefit other men who have sex with men who are at high risk for HIV/STI infection but do not test frequently enough to get diagnosed on a timely basis. You will benefit from this study with free and professional HIV/STI counselling and testing services, referral and treatment services if applicable. You will also get free condoms, lubricant and health manual.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

#### 6. What will happen to information about me?

By signing the consent form you consent to the research team collecting and using information about you for the research study, if you are eligible and willing to participate in this study. If you provide your permission the research team will store your data in a password-protected databank for 5 years. The data will be stored in a format where you will be identifiable. This is designed to match your data with you in follow-up visits in this study. However, only the custodians listed in the table above will have access to your original data. All identifying variables, including the initial of your surname, mobile phone number and date of birth, will be de-identified before data are transferred to a data analyst in this study. The custodians listed in the table above will ensure that your data is stored and managed appropriately and according to the relevant privacy laws. The data custodian will only share your data with researchers who are conducting HIV/STI related epidemiologic studies and only once these projects have received separate ethics approval from a Human Research Ethics Committee. All identifying variables, including initial of your surname, mobile phone number and date of birth, will be de-identified before data sharing.

26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

#### 7. How and when will I find out what the results of the research study are?

The research team intend to publish and report the results of the research study in a variety of ways, including academic conferences and journals. All information published will be done in a way that will not identify you. If you would like to receive a copy of the results you can let the research team know by adding your email within the consent form. We will only use these details to send you the results of the research. The results will also be made available via the school's website: kirby.unsw.edu.au.

#### 8. What if I want to withdraw from the research study?

If you do consent to participate, you may withdraw at any time. You can do so by completing the 'Withdrawal of Consent Form' which is provided at the end of this document. Alternatively you can ring the research team and tell them you no longer want to participate. If you decide to leave the research study, the researchers will not collect additional information from you. Your decision not to participate will not affect your relationship with the Guangdong Provincial Center for Skin Disease and STI Control, the Wuxi Municipal Center for Disease Control and Prevention, the Nanshan District Center for Chronic Disease Control and Prevention, the Kirby Institute, University of New South Wales, and the Sun Yat-sen University, Guangzhou

#### 9. What type of data will be stored in this data bank?

With your permission we would like to store the following types of data with the intention to share it and use it in future research projects.

- Socio-demographic characteristics, including your name (a pseudonym is ok), initial of your surname, mobile phone number, date of birth, ethnicity, marital status, educational level, income and profession.
- Sexual behaviours, including anal sex with men and vaginal sex with women and condom use during these sex.
- HIV/STI testing and diagnosis experiences
- Attitudes towards HIV pre-exposure prophylaxis
- Blood donation experiences
- Geo-social networking app use experiences
- Bio-specimen to test for HIV and other STIs

#### 10. What will happen to my data?

If you provide your permission the research team will store your data in a



password-protected databank. The data stored in a format where you will be identifiable. This is designed to match your data with you in follow-up visits in this study. However, only the custodians listed in the table above will have access to your original data. All identifying variables, including name (a pseudonym is ok), initial of your surname, mobile phone number and date of birth, will be de-identified before data are transferred to a data analyst in this study.

#### 11. Who will have access to my data?

Only the custodians listed in below will ensure that your data is stored and managed appropriately and according to the relevant privacy laws. The data custodian will only share your data with researchers who are conducting HIV/STI testing related epidemiologic studies and only once these projects have received separate ethics approval from a Human Research Ethics Committee. All identifying variables, including name (a pseudonym is ok), initial of your surname, mobile phone number and date of birth, will be de-identified before data sharing.

<b>Data Custodians</b>	<i>Mr. Yunyun Zhu</i>	<i>Guangdong Provincial Center for Skin Disease and STI Control, China</i>
------------------------	-----------------------	--

#### 12. How long will you store my data for?

We intend to store your data for 5 years. After 5 years, the data from the questionnaire will be deleted from the computer system and biospecimen will be disposed of as per biosafety practice in China.

#### 13. Can I withdraw my information from this databank?

If you no longer wish to have your data stored or do not wish to be contacted for research purposes you can withdraw your information by completing the withdrawal of consent form that is attached or by phoning the data custodian and letting them know.

#### 14. What should I do if I have further questions about my involvement in the research study?

The person you may need to contact will depend on the nature of your query. If you want any further information concerning this project or if you have any problems which may be related to your involvement in the project, you can contact the following member/s of the research team.

#### 15. Research Team Contact Details

<b>Name</b>	<i>Dr. Huachun Zou</i>
<b>Position</b>	<i>Research Fellow</i>
<b>Telephone</b>	<i>+61 2 9385 3132 or +86 20 8733 5651</i>
<b>Email</b>	<i>hzou@kirby.unsw.edu.au</i>

#### 16. Support Services Contact Details

We don't expect this study procedure to cause any distress, however if you experience feelings of distress as a result of participation in this study you can let the research team know and they will provide you with assistance. If at any stage during the project you become distressed or require additional support from someone not involved in the research please call:

<b>Name/Organisation</b>	<i>Dr. Weiyang Chen/T2T Project</i>
<b>Position</b>	<i>Research Assistant</i>
<b>Telephone</b>	<i>189 2249 3020</i>
<b>Email</b>	<a href="mailto:T2TStudy@outlook.com">T2TStudy@outlook.com</a>

**What if I have a complaint or any concerns about the research study?**

If you have any complaints about any aspect of the project, the way it is being conducted, then you may contact:

**Complaints Contact**

<b>Position</b>	Human Research Ethics Coordinator
<b>Telephone</b>	+ 61 2 9385 6222
<b>Email</b>	<a href="mailto:humanethics@unsw.edu.au">humanethics@unsw.edu.au</a>
<b>HC Reference Number</b>	HC16803

For peer review only



# BMJ Open

## A randomized controlled trial to evaluate the impact of sexual-health-clinic-based automated text message reminders on the testing of HIV and other sexually transmitted infections in men who have sex with men in China: protocol for the T2T Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015787.R2
Article Type:	Protocol
Date Submitted by the Author:	16-May-2017
Complete List of Authors:	Zou, Huachun; Sun Yat-sen University, School of Public Health Meng, Xiaojun; Wuxi Municipal Center for Disease Control and Prevention, Department of Infectious Disease Control Grulich, Andrew; The Kirby Institute, UNSW, Huang, Shuijie; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office Jia, Tianjian; Wuxi Municipal Center for Disease Control and Prevention, Department of Infectious Disease Control Zhang, Xuan; Wuxi Municipal Center for Disease Control and Prevention, Department of Infectious Disease Control Luo, Zhenzhou; Nanshan District Center for Chronic Disease Control and Prevention, STD Control Office Ding, Yi; Nanshan District Center for Chronic Disease Control and Prevention, STD Control Office Yang, Ligang; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office Huang, Jinmei; Guangdong Provincial Center for Skin Diseases and STDs Control, Chen, Weiyong; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office zheng, heping; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office Yang, Bin; Guangdong Provincial Center for Skin Disease and STI Control, STD Control Office
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Health services research, Health policy, Sexual health
Keywords:	Text message service, Reminder, HIV, STI, Men who have sex with men, Sexual health clinic

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-015787 on 10 July 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**A randomized controlled trial to evaluate the impact of  
sexual-health-clinic-based automated text message reminders on the  
testing of HIV and other sexually transmitted infections in men who  
have sex with men in China: protocol for the T2T Study**

Huachun Zou<sup>1,2#\*</sup>, Xiaojun Meng<sup>3#</sup>, Andrew Grulich<sup>2</sup>, Shujie Huang<sup>4,5</sup>, Tianjian Jia<sup>3</sup>,  
Xuan Zhang<sup>3</sup>, Zhenzhou Luo<sup>6</sup>, Yi Ding<sup>6</sup>, Ligang Yang<sup>4,5</sup>, Jinmei Han<sup>4,5</sup>, Weiyang  
Chen<sup>4,5</sup>, Heping Zheng<sup>4,5</sup> and Bin Yang<sup>4,5\*</sup>

1. School of Public Health, Sun Yat-sen University, Guangzhou, China
2. Kirby Institute, University of New South Wales, Sydney, Australia
3. Department of Infectious Disease Control, Wuxi Municipal Center for Disease Control and Prevention, Wuxi, China
4. Dermatology Hospital of Southern Medical University, Guangzhou, China
5. Guangdong Provincial Dermatology Hospital, Guangzhou, China
6. Nanshan District Center for Chronic Disease Control and Prevention, Shenzhen, China

# Huachun Zou and Xiaojun Meng contributed equally to this paper

**Corresponding authors**

Dr. Huachun Zou

School of Public Health, Sun Yat-sen University, Guangzhou, China

Email: zouhuachun@mail.sysu.edu.cn

Dr. Bin Yang

Dermatology Hospital of Southern Medical University, Guangzhou, China

Email: yangbin101@hotmail.com

## ABSTRACT

**Introduction:** The frequency of screening for HIV and other sexually transmitted infections (STIs) among men who have sex with men (MSM) is still low in China.

**Methods and analysis:** A sexual health clinic (SHC)-based randomized controlled trial will be conducted in Guangzhou, Wuxi and Shenzhen, China, enrolling 600 MSM. Eligibility will be judged by the pre-programed iPad-based questionnaire: 1) be  $\geq 18$  years of age, and 2) have had 2 or more male anal sex partners, or condomless anal sex with a casual male sex partner, or an STI history, in the past 6 months, and 3) provide a valid mobile number. Eligible men will be randomly allocated 1:1 to either Intervention Arm (with monthly text message reminding them to test for HIV/STIs) or Control Arm (without reminder). Men in both arms will complete a questionnaire onsite at enrollment and 12 months, and another questionnaire online at 6 months. Men in both arms will be tested for HIV, syphilis, anal gonorrhoea/chlamydia, and penile gonorrhoea/chlamydia at enrollment and 12 months. The primary outcome is the rate and frequency of HIV testing within the 12 months after enrolment. The secondary outcome is the rate of unprotected anal intercourse. An assessment of the cost-effectiveness of this intervention is also planned.

**Ethics and dissemination:** The study has been approved by the Ethical Review Committees of the University of New South Wales in Australia (HC16803), the Guangdong Provincial Center for Skin Disease and STI Control (GDDHLS-20160926) and Wuxi Center for Disease Control and Prevention (WXCDC2016009) in China. Study findings will be submitted to academic journals and disseminated to local health authorities.

**Trial registration number:** This study has been registered at the Chinese Clinical Trial Registry (<http://www.chictr.org.cn/enIndex.aspx>) and WHO International Clinical Trials Registry Platform (<http://www.who.int/ictrp/en/>), ID: ChiCTR-IPR-15006086.

## Keywords

Text message service; Reminder; HIV; STI; Men who have sex with men; Sexual

1  
2  
3 health clinic  
4  
5  
6

## 7 **ARTICLE SUMMARY**

8  
9

### 10 **Strengths and limitations of this study**

- 14 ■ No study has examined the role of sexual health clinic based automated short  
15 messaging services in the testing and detection of HIV/STIs in men who have sex  
16 with men (MSM) in China.
  - 17 ■ Findings from this study has the potential to help health authorities to develop new  
18 interventional strategies to control HIV/STIs among MSM in China.
  - 19 ■ This intervention, from judging eligibility to sending text message reminders, is  
20 wholly automated and requires limited human input, which can be easily replicated  
21 in other sexual health clinics in China and beyond.
  - 22 ■ Sexual behaviours and STI history during follow-up will be self-reported by  
23 participants, which may be subject to bias.
  - 24 ■ Loss to follow-up of participants is possible in this longitudinal study.
- 25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Men who have sex with men (MSM) in many countries are disproportionately affected by HIV and other sexually transmissible infections (STIs) such as gonorrhoea, chlamydia and syphilis<sup>1-4</sup>. More frequent screening for HIV and other STIs has the potential to improve detection of these largely asymptomatic infections, interrupting transmission and improving disease control<sup>5</sup>. Guidelines in a number of countries call for regular screening for HIV/STIs among MSM. For example, the US and Australian guidelines recommend that all MSM be screened for urethral and rectal chlamydia, pharyngeal and rectal gonorrhoea, syphilis and HIV at least once a year, with 3-6 monthly screening of MSM at higher-risk for HIV/STIs transmission<sup>6,7</sup>. However, available data suggest that the rate of screening for these infections among MSM is much lower than recommended in many countries<sup>8,9</sup>.

Significant increases in screening rates for gonorrhoea and chlamydia (Odds ratio (OR) range:1.4-1.9) have been demonstrated in observational studies using several different strategies: use of a computer alert on an electronic medical record<sup>10</sup>, the introduction of clinic guidelines on STI screening<sup>11</sup>, and short text messaging reminders for repeat STI screening<sup>12,13</sup>. Increases in syphilis testing (OR range: 2.3-21.4) were found using the following strategies: advocating regular serological screening for syphilis during routine HIV care<sup>14</sup>; including syphilis serology testing routinely with blood tests performed as part of HIV monitoring<sup>15</sup>; use of a computer alert on an electronic medical record<sup>16</sup>; and an electronic medical record system with a reminder to clinicians to enhance syphilis retesting following syphilis treatment<sup>17</sup>. A

1  
2  
3  
4 before-and-after study in Australia using existing clinical and behavioral data of  
5  
6 clients attending a major sexual health clinic (SHC) found that automated,  
7  
8 computer-generated text message service (SMS) 3-monthly reminders doubled the  
9  
10 testing rate for HIV, syphilis, gonorrhoea and chlamydia among MSM<sup>18</sup>. That study  
11  
12 also demonstrated an increased detection rate for syphilis, gonorrhoea and chlamydia,  
13  
14 but not for HIV<sup>18</sup>. Another before-and-after study in Australia found increased  
15  
16 HIV/STI re-testing rates among MSM as a result of 3-6 monthly SMS reminders at a  
17  
18 large SHC<sup>12</sup>. However until now there has been no randomized controlled trial to  
19  
20 confirm these effects.  
21  
22  
23  
24

25  
26 MSM in China are increasingly engaging in high risk sexual behaviors such as low  
27  
28 rate of condom use in anal sex, multiple concurrent partnerships and drug use during  
29  
30 sex<sup>19</sup>. The rates of HIV and STIs among this population are high and increasing. The  
31  
32 estimated HIV prevalence among MSM in China increased sharply over the past  
33  
34 decade: from 0.6% in 2003 to 8% in 2015<sup>20,21</sup>. Accordingly the proportion of MSM  
35  
36 among all people living with HIV/AIDS also climbed steadily: from 7% in 2005 to 25%  
37  
38 in 2015<sup>22,23</sup>. Many MSM in China were also infected with other STIs. A  
39  
40 meta-analysis found that the prevalence levels of STIs among MSM in China were 6%  
41  
42 for chlamydia, 2% for genital warts, 2% for gonorrhoea, 9% for hepatitis B, 1% for  
43  
44 hepatitis C, 66% for human papillomavirus and 11% for herpes simplex virus-2  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

24. However the testing rate for these infections was suboptimal. A systematic review  
found that less than 40% of MSM in China had tested for HIV in the past year<sup>25</sup>.  
Nearly half of MSM in China had a baseline CD4+ Cell count  $\leq 350$  per mm<sup>3</sup> at

1  
2  
3  
4 HIV diagnosis<sup>26</sup>. The rates of testing for other STIs were also low<sup>27,28</sup>. It is urgently  
5  
6  
7  
8  
9  
10 needed to introduce an effective intervention that can increase testing and help  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

achieve timely diagnosis of HIV and other STIs among MSM in China.

Our study aims to use a randomized controlled trial to evaluate the role of SHC-based automated text message services in the testing and detection of HIV and other STIs among MSM in China.

## METHODS AND ANALYSIS

### Overview

The proposed protocol (dated December 8, 2016) was developed and facilitated by collaborations between experienced investigators from the Kirby Institute, the University of New South Wales (UNSW) in Sydney, Australia, Dermatology Hospital of Southern Medical University (DHSMU) in Guangzhou, China, Wuxi Center for Disease Control and Prevention (CDC) in Wuxi, China, Nanshan District Center for Chronic Disease Control and Prevention (CCDC) in Shenzhen, China, and Sun Yat-sen University in Guangzhou, China. The study will randomize 600 men who have sex with men (MSM) 1:1 into Intervention Group (with reminders) and Control Group (without reminders) and evaluate the role of SHC-based automated text message services in the testing and detection of HIV/STIs among MSM. A sample size of 300 MSM in each group will provide 90% power to detect a 15.0% (from 50% to 65%) difference in the proportion of HIV testing in the past 12 months between the two groups, considering 30% of loss-to-follow-up at 12 months.



## Objectives

The primary objective of this study is to determine the impact of SHC-based automated text message services on the testing and detection of HIV. The secondary objective is to determine the impact of SHC-based automated text message services on the change in sexual behaviors. The additional analysis is to evaluate the costs and incremental cost-effectiveness of the intervention.

## Study settings

This study will be based at the SHCs affiliated to DHSMU, Wuxi CDC and Shenzhen Nanshan CCDC. The population in Guangzhou, Wuxi and Shenzhen was around 13, 6 and 13 million, respectively, all with per capita gross domestic product (GDP) of over USD20,000 in 2014<sup>29-31</sup>. The three SHCs provide HIV/syphilis voluntary counseling and testing (VCT) and HIV/STI treatment services to over 25,000 clients annually, 10% of whom were estimated to be MSM (data not published). These three SHCs are equipped with microbiological diagnostic units and capable of timely testing and treating HIV and other STIs, including syphilis, gonorrhoea, chlamydia trachomatis and genital warts.

## Inclusion criteria

MSM attending the three clinics will be invited to join the study if they meet the following criteria: 1) anatomical men aged 18 years or older; 2) having over 2 male

1  
2  
3  
4 anal sex partners, or condomless anal sex with a casual male sex partner, or an STI  
5  
6 history including gonorrhoea, syphilis, anogenital warts, genital herpes and chlamydia  
7  
8 trachomatis, in the past 6 months; 3) possessing a mobile phone; 4) willing to provide  
9  
10 informed consent for the collection of demographics, sexual behaviors and HIV/STI  
11  
12 testing experiences and biological samples to test for HIV/STIs; 5) residing in a study  
13  
14 city in the next 12 months or visiting a study city frequently enough to participate in  
15  
16 the study; 6) willing to register testing results if they test elsewhere during the study.  
17  
18  
19

#### 20 21 22 23 24 Exclusion criteria

25  
26 MSM who meets one or more criteria listed below will be excluded: 1) has severe  
27  
28 psychiatric illnesses; 2) unable to read or use the iPad questionnaire; 3) does not speak  
29  
30 or read the Chinese languages  
31  
32  
33

#### 34 35 36 37 Study procedures

38  
39 We will use the following strategies for achieving adequate participant enrolment to  
40  
41 reach target sample size: 1) At the three clinics, study posters will be put in the  
42  
43 waiting area, consultation rooms and male toilets. 2) The clinics will work with local  
44  
45 MSM community organisations to refer potentially eligible MSM, who will physically  
46  
47 attend the three clinics to complete the enrolment. 3) Doctors will encourage  
48  
49 participants to introduce our study to their peers. A study phone number will be  
50  
51 designated to this study. This randomized controlled trial will consist of  
52  
53 computer-assisted self-interview (CASI) and automated, computer-generated SMS  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 reminders among 600 MSM attending the SHCs. It will be conducted over 21-24  
5  
6 months: 3 months of logistic preparation, 3-6 months of recruitment, 12 months of  
7  
8 follow up and 3 months of report preparation. Detailed recruitment procedure is  
9  
10 described in Figure 1 and Table 1. Over a 3-6 months recruiting period, all male  
11  
12 clients presenting to the clinic will be given an information flyer by a receptionist who  
13  
14 is not directly involved in the study. The flyer will include basic information about the  
15  
16 study, including that it is a study for MSM. The receptionist will ask each male client  
17  
18 to read the flyer and to visit the study research assistant who sits at a nearby desk, if  
19  
20 they are interested in finding out more about the study. Clients may be enrolled and  
21  
22 passed on to the research assistant when they are seen by a clinician after leaving the  
23  
24 waiting area. Those male clients who express interest in participating will see the  
25  
26 study research assistant, who will take them to a private clinic room where an iPad  
27  
28 questionnaire system is installed. The study research assistant will explain what the  
29  
30 study involves and go through the iPad-based full Participant Information and  
31  
32 Consent Form (PICF) with potential eligible participants. Men will have time to read  
33  
34 the PICF, to ask questions, and to decide if they will participate in the study. Men will  
35  
36 need to click the “Agree” button to consent before completing an iPad-based  
37  
38 questionnaire. The study research assistant will ask consented participants to complete  
39  
40 the iPad-based questionnaire on their own, in the private room. They will be  
41  
42 instructed that if they have any further questions, they should ask the research  
43  
44 assistant who will be at a desk, outside of the private room. The questionnaire will  
45  
46 collect information on sexual behaviours, HIV/STI testing behaviours and diagnosis  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 history and alcohol/tobacco/drug use. The pre-programmed logic in the questionnaire  
5  
6 will judge if a participant is actually eligible, based on sexual behavior variables.  
7  
8 Those who are not eligible will be thanked and released back into the clinic waiting  
9  
10 room for their routine clinical care. Eligible participants will provide a valid mobile  
11  
12 phone number and then be automatically randomised into either intervention or  
13  
14 control group, by the computer. They will then receive a text message with a code as  
15  
16 their Study ID. When they finish the PICF and questionnaire participants will see the  
17  
18 study research assistant who will guide them to see a doctor for bio-specimen  
19  
20 collection, followed by routine clinical care, if necessary. Eligible MSM who opt out  
21  
22 of the study will be recorded and asked about reasons to decline. During the whole  
23  
24 study period, the clients, clinicians, research assistants, and data analysts will be  
25  
26 blinded after assignment to intervention. To maintain the overall quality and  
27  
28 legitimacy of the trial, unblinding should occur only in exceptional circumstances  
29  
30 when knowledge of the intervention can substantially increase HIV/STI retesting rate  
31  
32 among MSM. We will judge this on the basis of the interim data analysis. If  
33  
34 unblinding is deemed to be necessary, the steering committee of the study will hold a  
35  
36 discuss and make a decision in consultation with the ethics committees.  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Detailed study procedure is described in Figure 2. We acknowledge that directly  
47  
48 mentioning of sensitive words such as HIV and STIs in SMS reminders may lead to  
49  
50 the exposure of privacy of participants to others. As a result, we will avoid using these  
51  
52 sensitive words in actual SMS reminders. Instead, in actual reminders we will use  
53  
54 “*Little A*” to refer to “HIV”, “*Little B*” to refer to “STIs”, “*Health check*” to refer to  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 “HIV/STI testing”, “*Self health check*” to refer to “HIV self-testing at home”, and  
5  
6 “health kit” to refer to “condoms/lubes/MSM health manuals”. We will clarify this in  
7  
8 the PICF. All messages will include a withdrawal option.  
9

10  
11 For MSM in the Intervention Group, upon enrolment, they will receive Message A:  
12  
13 “A gentle reminder: If you plan to have a health check again in the next 12 months,  
14  
15 welcome to our center. If you do it elsewhere (including self-health check) in the next  
16  
17 12 months, please register the results online at the following link: \*\*\*\*\*. Every time  
18  
19 you register we will compensate you with an electronic mobile phone credit of  
20  
21 CNY10 (USD1.5). If you change your mobile phone number in the next 12 months  
22  
23 please let us know.” When they register online, participants need to enter the mobile  
24  
25 phone number that was validated at enrolment and the initial of their surname to enter  
26  
27 the questionnaire. This is designed to avoid the exposure of sensitive questions to a  
28  
29 non participant. On the second day after enrolment, they will receive Message B: “A  
30  
31 gentle reminder: Little A and little B are spreading rapidly and it’s hard to detect by  
32  
33 yourself. Your best protection is a regular check-up (e.g. every 3 months). If you  
34  
35 change your mobile phone number please let us know.” Starting from day 30, they  
36  
37 will receive Message C every 30 days: “A gentle reminder: If you have not had a  
38  
39 health check in the past 3 months please do so as soon as possible. If you change your  
40  
41 mobile phone number please let us know.” On day 190, 10 days after they receive  
42  
43 Message C on day 180, they will receive Message D, reminding them to complete an  
44  
45 online survey about their sexual life and testing behaviors in the past 6 months: “A  
46  
47 gentle reminder: please complete a survey at the following link at your earliest  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 convenience: \*\*\*\*\*. We will compensate you with an electronic mobile phone credit  
5  
6 of CNY50 (USD8). If you change your mobile phone number please let us know.” On  
7  
8 day 370, 10 days after they receive Message C on day 360, they will receive Message  
9  
10 E, reminding them to complete an onsite survey about their sexual life and testing  
11  
12 behaviours in the past 6 months: “A gentle reminder: please attend our center to  
13  
14 complete the final survey. We will compensate you with an electronic mobile phone  
15  
16 credit of CNY100 (USD16), together with a health kit. If you change your mobile  
17  
18 phone number please let us know.” At enrollment and 12 months men will be tested  
19  
20 for HIV, syphilis, urethral and anal chlamydia and gonorrhoea, and examined for  
21  
22 anogenital warts. CD4+ testing will be provided for men diagnosed with HIV.  
23  
24 HIV/STIs will be treated as per relevant treatment guidelines in China. At 6 and 12  
25  
26 months men will also be asked questions about their experience of the intervention  
27  
28 including the impact of the intervention on their everyday life, mental health, sexual  
29  
30 health and general health (Figure 2).  
31  
32  
33  
34  
35  
36  
37  
38

39 MSM in the Control Group will receive Message A upon enrolment, Message D on  
40  
41 day 190 and Message E on 370. They will not receive Messages B and C. They will  
42  
43 complete the same questionnaire as men in the intervention group do at enrolment, 6  
44  
45 months and 12 months and test for above-mentioned HIV/STIs at enrolment and 12  
46  
47 months. They will not be asked about their experience of the intervention.  
48  
49  
50

51 The 10 days' time gap between Messages C and D is planned to give men in both  
52  
53 groups enough time to attend a SHC upon receiving Message C. Besides men's  
54  
55 mobile phone number (compulsory) we will also try to collect other contact  
56  
57  
58  
59  
60

1  
2  
3  
4 information (optional), including email, QQ and WeChat ID (instant online messaging  
5  
6 applications frequently used in China). At 6 and 12 months, men will be contacted  
7  
8 with the additional contact information if they do not complete a designated survey  
9  
10 within 7 days after Messages D and E are sent. Men who register testing information  
11  
12 online or fill in an online questionnaire at 6 months will need to enter their mobile  
13  
14 number to access the actual questionnaire. This is designed in case another person  
15  
16 oversees the URL address from Message A. The process from commencing CASI to  
17  
18 the regular dispatch of the reminders will be entirely automated, requiring no human  
19  
20 input.  
21  
22  
23  
24

25  
26 For men in both groups, at enrolment and 12 months, a study nurse will collect a  
27  
28 swab from the anal canal to test for anal gonorrhoea and chlamydia, and 5 ml of blood  
29  
30 to test to test for HIV and syphilis. Participants will self-collect a urine sample to test  
31  
32 for urethral gonorrhoea and chlamydia. A doctor will check ano-genital warts for each  
33  
34 participant. The HIV serologic status will be screened by ARCHITECT HIV Ag/Ab  
35  
36 Combo assay (Abbott Laboratories, Abbott Park, Illinois, USA). Positive samples will  
37  
38 be further screened by enzyme linked immunosorbent assay (ELISA) (Bio-Rad  
39  
40 Laboratories, CA, USA). Samples positive for ELISA will be confirmed by the  
41  
42 HIV-1/2 Western blot assay (HIV Blot 2.2 WB; Genelabs Diagnostics, Singapore).  
43  
44 Confirmed HIV cases will be tested for CD4+ T Cell count. Syphilis will be screened  
45  
46 by the toluidine red unheated serum test (TRUST) (RSbio, Shanghai, China) and  
47  
48 samples positive for TRUST will be confirmed by treponema pallidum particle assay  
49  
50 (TPPA) (Fuji ReBio, Tokyo, Japan). Anal and urethral gonorrhoea and chlamydia will  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 be tested using polymerase chain reaction (PCR) (Roche Diagnostics, Shanghai,  
5  
6 China). Ano-genital warts will be checked by a doctor with the assistance of acetic  
7  
8 acid test.  
9

### 10 11 12 13 14 **Incentives and retention**

15  
16 Study participants will receive health education materials, condoms and lubricant  
17  
18 upon completion of the CASI questionnaire at enrolment and 12 months. Participants  
19  
20 will receive an electronic mobile phone credit of CNY50 (USD8), CNY50 (USD8)  
21  
22 and CNY100 (USD16), upon completion of the surveys at enrolment, 6 months and  
23  
24 12 months. Participants who test elsewhere will receive an additional electronic  
25  
26 mobile phone credit CNY 10 (USD 1.5) each time they register testing results online.  
27  
28  
29  
30  
31  
32  
33

### 34 **Statistical methods**

#### 35 36 ***Power/sample size***

37  
38 We used the following formula to calculate sample size:  
39

$$40  
41  
42  
43  
44 n = \frac{(Z_{\alpha} \sqrt{2pq} + Z_{\beta} \sqrt{p_0q_0 + p_1q_1})^2}{(p_1 - p_0)^2}$$

45 In this formula,  $Z_{\alpha}$  and  $Z_{\beta}$  represent the Z boundaries under the standard normal  
46  
47 distribution;  $p_1$  and  $p_0$  represents proportion of a parameter in the intervention group  
48  
49 and control group, respectively;  $p$  equals to the average of  $p_1$  and  $p_0$ ;  $q=1-p$ . We used  
50  
51 2 parameters in the calculation of sample size: (a) proportion of men who have HIV  
52  
53 testing during the 12 months after baseline; (b) proportion of men who have  
54  
55 condomless anal sex during the 12 months after baseline. We assumed a two-sided  
56  
57  
58  
59  
60



1  
2  
3  
4 hypothesis test with a 5% significance level ( $Z_{\alpha/2}=1.96$ ), a desired power of 90%  
5  
6 ( $Z_{\beta}=1.28$ ), and that both groups will have the same number of observations.  
7  
8

9 Using parameter (a), the rate of HIV testing in the past 12 months among MSM in  
10 Wuxi in 2014 was 50% ( $p_0$ ), and this figure was expected to increase to 65% ( $p_1$ )  
11 according to a before-and-after study in Australia<sup>18</sup>. This resulted in a sample size of  
12 225 in each group. Khosropour et al., retained around 70% of MSM for 12 months  
13 using bimonthly follow-up surveys through text messages<sup>30</sup>. We will adopt a  
14 number of strategies to minimize the loss-to-follow-up rate: educating investigators  
15 about the culture in MSM community and develop rapport with participants;  
16 verifying mobile number at enrolment; contacting participants on days 190 and 370  
17 using various messaging softwares/apps such as WeChat, QQ, email, etc; and  
18 reasonable incentives. Considering a loss-to-follow-up rate of 30%, a sample size of  
19 300 MSM in each group will be needed.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 *Analysis plan*

40 Analyses will be performed using STATA 13.0 (College Station, TX, USA)  
41 statistical analysis software. All effects will be estimated with a 95% confidence  
42 intervals and p-values from the corresponding hypothesis tests. Statistical  
43 significance will be taken as two-sided p-value less than 0.05, with no adjustment for  
44 multiple comparisons. Characteristics of groups will be summarised at baseline and  
45 across study arms. Mean duration of study follow-up will be compared by group.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Primary analysis will compare randomized groups of MSM using an intention to  
5  
6 treat approach. Initial analyses will be simple, unadjusted comparisons of  
7  
8 randomised groups. If there appears to be any important imbalances between  
9  
10 randomised groups in terms of baseline covariates, adjusted analyses will also be  
11  
12 performed.  
13  
14

15  
16 The primary outcome is the proportion of HIV/STIs testing and detection during  
17  
18 the past 12 months, comparing the intervention and control arms. At the end of the  
19  
20 study: 1) we will use Cox proportional hazard models with Kaplan Meier plots and  
21  
22 log-rank test to explore the cumulative rate of reported HIV/STIs testing and  
23  
24 detection during the previous 12 months, comparing the two groups. Number of  
25  
26 testing and detection of each infection will also be compared. 2) we will use  
27  
28 Chi-square test to compare the proportion of reported HIV/STIs testing and detection  
29  
30 during the previous 12 months before intervention with that during the 12 months  
31  
32 after intervention, within Intervention Group. Number of testing and detection of  
33  
34 each infection will also be compared.  
35  
36  
37  
38  
39  
40

41 The second outcome is the proportion of condomless anal sex during the past 12  
42  
43 months. At the end of the study: 1) we will use Chi-square test to compare the  
44  
45 proportion of reported condomless anal sex during the previous 12 months between  
46  
47 the two groups. 2) we will use rank sum test to compare the number of reported anal  
48  
49 sex partners during the previous 12 months between the two groups. 3) we will use  
50  
51 Chi-square test to compare the proportion of reported condomless anal sex during  
52  
53 the previous 12 months before intervention with that during the 12 months after  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 intervention, within Intervention Group. 4) we will use rank sum test to compare the  
5  
6 number of reported anal sex partners during the previous 12 months before  
7  
8 intervention with that during the 12 months after intervention, within Intervention  
9  
10 Group.  
11  
12

### 13 14 15 16 **Additional analyses**

#### 17 18 *Cost and cost-effectiveness evaluation*

19  
20 Although some studies have assessed the cost-effectiveness of HIV testing methods  
21  
22 among high-risk populations in some regions <sup>32-38</sup>, whether the intervention in this  
23  
24 study is cost-effective is unclear. As a result, the costs and incremental  
25  
26 cost-effectiveness of the intervention compared to control will be evaluated, using  
27  
28 standard methods of cost-effectiveness analysis <sup>39</sup>. Our analysis will include the  
29  
30 costs of the self-registration and SMS reminding system development and  
31  
32 maintenance, HIV/STI testing and counseling, follow-up, and treatment. All costs  
33  
34 will be measured from a societal perspective, and inflated to 2015 Chinese Yuan at a  
35  
36 discounting rate of 3% annually.  
37  
38  
39  
40  
41  
42  
43  
44  
45

#### 46 47 *Cost-Effectiveness analysis*

48  
49 Based on incremental cost-effectiveness analysis, we will calculate the incremental  
50  
51 cost for one additional newly identified HIV/STI case, and one additional early HIV  
52  
53 case, using the following formula <sup>39</sup>:  
54

$$55 \text{ ICER}_{ij} = (C_i - C_j) / (E_i - E_j)$$

56  
57  
58  
59  
60

### *Markov model based Cost-Utility analysis*

We will develop a decision model to reflect when successful HIV/STI detection, follow-up, and treatment occur for a cohort of MSM with/without intervention, and then a Markov model estimating the lifecycle of MSM from entering the cohort until death, to examine the incremental cost-utility of intervention. Effectiveness is measured as quality adjusted life-years (QALYs) gained. We assume that QALYs accrues by early initiation of antiretroviral therapy (ART) following early HIV detection. According to the actual situation in China, the natural history of HIV/AIDS is categorized as the following stages: asymptomatic HIV, symptomatic HIV, AIDS and death. Health states summarizes current status based on CD4+ T cell count, quality of life, ART usage and resource use. ART and CD4+ T cell count combined determines the transition probabilities and mortality rates<sup>40 41</sup>. The model will assess HIV status, stage transfer and its consequences among MSM with incident HIV infection on an annual basis. All the parameters used in this model will be compiled from a variety of sources, including literature review, ongoing cohort studies and investigations, surveillance data or unpublished data from Wuxi and other parts of China.

In this study, we assume that: (1) stage transition in the Markov model happens once a year, (2) once an HIV infected man receives ART, he will complete the entire treatment procedure. To account for assumptions and uncertainties of this model, we will perform one-way sensitivity analyses on all model parameters. For all the

1  
2  
3  
4 probability variables, our ranges for sensitivity analyses represent our judgment of  
5  
6 the variation on the basis of both the literature and discussion with experts.  
7  
8  
9

### 10 **Sample/data storage**

11  
12 All electronic questionnaires, consent forms will be stored in a password-protected  
13  
14 computer at the information center at DHSMU as per its common practice. The data  
15  
16 will be stored in a format that is identifiable. This is designed to match data with  
17  
18 individual participants in follow-up visits in this study. However, only the custodian  
19  
20 will have access to the original data. All identifying variables, including name (a  
21  
22 pseudonym is ok), initial of participant's surname, mobile phone number and date of  
23  
24 birth, will be de-identified before data are transferred to a data analyst in this study.  
25  
26 The custodian will ensure that data is stored and managed appropriately and  
27  
28 according to the relevant privacy laws. The data custodian will only share data with  
29  
30 researchers who are conducting HIV/STI testing related epidemiologic studies and  
31  
32 only once these projects have received separate ethics approval from a Human  
33  
34 Research Ethics Committee. All identifying variables, including name (a pseudonym  
35  
36 is ok), initial of participant's surname, mobile phone number and date of birth, will  
37  
38 be de-identified before data sharing. Bio-specimen collected at a given site will be  
39  
40 stored at the corresponding participatory institution.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 **ETHICS AND DISSEMINATION**

52  
53  
54  
55  
56 The study has been approved by the Ethical Review Committees of the University of  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

New South Wales in Australia (HC16803), the Dermatology Hospital of Southern Medical University (GDDHLS-20160926) and Wuxi Center for Disease Control and Prevention (WXCDC2016009) in China. We anticipate that the benefits of study participation will outweigh any risks, including loss of confidentiality and privacy of clinical information. Participants will benefit from frequent testing and early diagnosis of HIV/STIs and timely treatment if positive. The findings of the study will be disseminated to local and national government in China as well as the wider academic audience and public health organizations through peer-reviewed publications and international conferences.

## DISCUSSION

This study protocol describes a randomized controlled trial designed to increase the testing and detection of HIV and other STIs among Chinese MSM through computer-assisted self-interview and automated computer generated reminders. Firstly, we seek to develop a platform requiring limited investment and human power that could be easily replicated and deployed in other SHCs in China and beyond. As such, one of the challenges in designing the intervention was the acceptance of it among target population-MSM in China-a population that has long been marginalized and discriminated against. Fortunately in our unpublished pre-trial study, almost 80% of MSM in the community were willing to take such an intervention. It is estimated that this rate would be even higher among MSM attending SHCs. Other key challenges to this study include the need to sustain the

1  
2  
3  
4 motivation of clinic staff to participate in the study while addressing the multiple  
5  
6 competing health priorities. Secondly, we will be able to understand MSM with what  
7  
8 characteristics are more likely to take this intervention and barriers that prevent other  
9  
10 MSM from taking this intervention. This will help develop an intervention that is  
11  
12 contextualized and tailored to the characteristics of MSM. Thirdly, if successful, this  
13  
14 intervention with high potential cost-effectiveness will contribute to the compilation  
15  
16 of the fabric of quality SHCs and health providers that will eventually be readily  
17  
18 available to MSM at their finger tips. This will greatly encourage and facilitate them  
19  
20 to test for HIV/STIs on a more frequent basis. Lastly, results from this study may  
21  
22 facilitate the development of proactive interventions strategies targeting other at-risk  
23  
24 populations, such as female sex workers and their clients, and drug users, etc. to  
25  
26 increase the testing and detection of HIV and other STIs and hence prevent the  
27  
28 transmission of these infections.  
29  
30  
31  
32  
33  
34  
35

36 This intervention has its limitations: Firstly, the 12-months research period is a  
37  
38 long commitment for MSM as many of them are quite mobile. The retention rate  
39  
40 could be compromised by 12 months. To tackle this problem we will verify  
41  
42 participants' mobile phone number at enrolment and remind them to update their  
43  
44 mobile number every 30 days. Additionally we will also use other contact  
45  
46 information reported by participants to achieve the highest possible retention rate.  
47  
48 Secondly, men could forget to register testing experience from other venues. To  
49  
50 tackle this problem, we will remind them to do this in Message A at enrolment.  
51  
52 Because a similar reminder during the study would potentially bring about  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 contamination to the intervention, we will not send further reminders. Thirdly, as  
5  
6 this intervention will be conducted in metropolitan cities, the results may not apply  
7  
8 to that in other settings.  
9

10  
11 In summary the knowledge gained from this study may be used to design similar  
12  
13 protocols with a higher number of participants and appropriate intervention  
14  
15 strategies to reduce the burden of HIV and other STIs among MSM, a population  
16  
17 who is heavily burdened by these infections. Additionally, if the results are positive,  
18  
19 we will scale up this practice in more SHCs across China.  
20  
21  
22  
23  
24  
25

## 26 **Acknowledgments**

27  
28 We thank Dr. Qianqian Xin from the Capital Institute of Pediatric in Beijing, Dr. Gang  
29  
30 Zeng from Alere Inc Beijing and Dr. Jinghua Li from Sun Yat-sen University for their  
31  
32 comments to the protocol.  
33  
34  
35  
36

## 37 **Authors' contribution**

38  
39 Huachun Zou and Xiaojun Meng initiated this research plan and designed this  
40  
41 protocol with Bin Yang and Andrew Grulich consulting on ethics and feasibility of  
42  
43 the research. Zhenzhou Luo, Tianjian Jia, Xuan Zhang, Yi Ding and Ligang Yang  
44  
45 provided expertise on recruitment and sample collection and will supervise these  
46  
47 aspects at the three study clinics. Jinmei Huang, Shujie Huang and Heping Zheng  
48  
49 provided expertise on sample testing and storage. Weiying Chen helped with the  
50  
51 design of questionnaire and recruitment methods.  
52  
53  
54

## 55 **Funding**

56  
57 This work was supported by a grant from Australian National Health and Medical  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Research Commission (NHMRC) Early Career Fellowship (APP1092621) and research grants from Guangdong Provincial Center for Skin Disease and STI Control (YCS201669), Wuxi municipal health and Family Planning Commission (MS201613), Wuxi Municipal Science and Technology Bureau (CSZ0N1512) and Nanshan District Center for Chronic Disease Control and Prevention. The funding bodies other than NHMRC participated in study design, data collection and analysis, preparation of the manuscript, and the decision to publish.

### Competing interests

All authors declare no competing interests.

### References

1. Hu J, Gu X, Tao X, et al. Prevalence and Trends of HIV, Syphilis, and HCV in Migrant and Resident Men Who Have Sex with Men in Shandong, China: Results from a Serial Cross-Sectional Study. *PLoS One*. 2017;12:e0170443.
2. Hernandez I, Johnson A, Reina-Ortiz M, et al. Syphilis and HIV/Syphilis Co-infection Among Men Who Have Sex With Men (MSM) in Ecuador. *Am J Mens Health*. 2016.
3. Vodstrcil LA, Fairley CK, Fehler G, et al. Trends in Chlamydia and Gonorrhoea Positivity among Heterosexual Men and Men who have sex with Men attending a large urban sexual health service in Australia, 2002-2009. *BMC Infect Dis*. 2011;11:158.
4. Keshinro B, Crowell TA, Nowak RG, et al. High prevalence of HIV, chlamydia and gonorrhoea among men who have sex with men and transgender women attending trusted community centres in Abuja and Lagos, Nigeria. *J Int AIDS Soc*. 2016;19:21270.
5. Zou H, Fairley CK, Guy R, et al. The efficacy of clinic-based interventions aimed at increasing screening for bacterial sexually transmitted infections among men who have sex with men: a systematic review. *Sex Transm Dis*. 2012;39:382-387.
6. Australian Sexually Transmitted Infection and HIV Testing Guidelines for Asymptomatic Men Who Have Sex with Men 2014. Available at: [http://stipu.nsw.gov.au/wp-content/uploads/STIGMA\\_Testing\\_Guidelines\\_Final\\_v5.pdf](http://stipu.nsw.gov.au/wp-content/uploads/STIGMA_Testing_Guidelines_Final_v5.pdf). Verified on March 5, 2015.
7. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010;59:1-110.
8. Witzel TC, Melendez-Torres GJ, Hickson F, et al. HIV testing history and preferences for future tests among gay men, bisexual men and other MSM in England: results from a cross-sectional study. *BMJ Open*. 2016;6:e011372.
9. Marcus U, Gassowski M, Drewes J. HIV risk perception and testing behaviours among men having sex with men (MSM) reporting potential transmission risks in the previous 12

- months from a large online sample of MSM living in Germany. *BMC Public Health*. 2016;16:1111.
10. Lister NA, Smith A, Fairley CK. Introduction of screening guidelines for men who have sex with men at an STD clinic, the Melbourne Sexual Health Centre, Australia. *Sex Health*. 2005;2:241-244.
  11. Ryder N, Bourne C, Rohrsheim R. Clinical audit: adherence to sexually transmitted infection screening guidelines for men who have sex with men. *Int J STD AIDS*. 2005;16:446-449.
  12. Bourne C, Knight V, Guy R, et al. Short message service reminder intervention doubles sexually transmitted infection/HIV re-testing rates among men who have sex with men. *Sex Transm Infect*. 2011;87:229-231.
  13. Nyatsanza F, McSorley J, Murphy S, et al. 'It's all in the message': the utility of personalised short message service (SMS) texts to remind patients at higher risk of STIs and HIV to reattend for testing-a repeat before and after study. *Sex Transm Infect*. 2016;92:393-395.
  14. Cohen CE, Winston A, Asboe D, et al. Increasing detection of asymptomatic syphilis in HIV patients. *Sex Transm Infect*. 2005;81:217-219.
  15. Bissessor M, Fairley CK, Leslie D, et al. Frequent screening for syphilis as part of HIV monitoring increases the detection of early asymptomatic syphilis among HIV-positive homosexual men. *J Acquir Immune Defic Syndr*. 2010;55:211-216.
  16. Hotton AL, Gratzner B, Pohl D, et al. Factors associated with repeat syphilis testing at a large urban LGBT health clinic: Chicago, IL 2002-2008. *Sex Transm Dis*. 2010;38:205-209.
  17. Bissessor M, Fairley CK, Leslie D, et al. Use of a computer alert increases detection of early, asymptomatic syphilis among higher-risk men who have sex with men. *Clin Infect Dis*. 2011;53:57-58.
  18. Zou H, Fairley CK, Guy R, et al. Automated, computer generated reminders and increased detection of gonorrhoea, chlamydia and syphilis in men who have sex with men. *PLoS One*. 2013;8:e61972.
  19. Zou H, Wu Z, Yu J, et al. Sexual risk behaviors and HIV infection among men who have sex with men who use the internet in Beijing and Urumqi, China. *J Acquir Immune Defic Syndr*. 2010;53 Suppl 1:S81-87.
  20. Meng X, Zou H, Beck J, et al. Trends in HIV prevalence among men who have sex with men in China 2003-09: a systematic review and meta-analysis. *Sex Health*. 2013;10:211-219.
  21. China Daily. Gay stigma hindering HIV prevention in China. Available at: [http://m.chinadaily.com.cn/en/2015-12/01/content\\_22596045.htm](http://m.chinadaily.com.cn/en/2015-12/01/content_22596045.htm). Verified on: August 30, 2016.
  22. Lu F, Wang N, Wu Z, et al. Estimating the number of people at risk for and living with HIV in China in 2005: methods and results. *Sex Transm Infect*. 2006;82 Suppl 3:iii87-91.
  23. China Daily. Gay men hit hard by HIV/AIDS epidemic. Available at: [http://europe.chinadaily.com.cn/china/2015-11/20/content\\_22486775.htm](http://europe.chinadaily.com.cn/china/2015-11/20/content_22486775.htm). Verified on: August 30, 2016.
  24. Chow EP, Tucker JD, Wong FY, et al. Disparities and risks of sexually transmissible infections among men who have sex with men in China: a meta-analysis and data synthesis. *PLoS One*. 2014;9:e89959.
  25. Zou H, Hu N, Xin Q, et al. HIV testing among men who have sex with men in China: a systematic review and meta-analysis. *AIDS Behav*. 2012;16:1717-1728.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
26. Tang H, Mao Y, Shi CX, et al. Baseline CD4 cell counts of newly diagnosed HIV cases in China: 2006-2012. *PLoS One*. 2014;9:e96098.
  27. Davis A, Best J, Luo J, et al. Risk behaviours, HIV/STI testing and HIV/STI prevalence between men who have sex with men and men who have sex with both men and women in China. *Int J STD AIDS*. 2015.
  28. Lin L, Nehl EJ, Tran A, et al. Sexually transmitted infection testing practices among 'money boys' and general men who have sex with men in Shanghai, China: objective versus self-reported status. *Sex Health*. 2014;11:94-96.
  29. Wuxi Municipal Government. Wuxi Economic and Social Development Statistical Report 2015. Available at: <http://www.wuxi.gov.cn/014006438/doc/2015/2/186988.shtml>. Verified: March 17, 2015.
  30. Guangzhou Economic and Social Development Statistics Bulletin 2015 (in Chinese). Available at: [http://www.gzstats.gov.cn/gzsq/201112/t20111229\\_27422.htm](http://www.gzstats.gov.cn/gzsq/201112/t20111229_27422.htm). Verified on: February 15, 2016.
  31. Shenzhen Municipal Bureau of Statistics. Shenzhen economic data 2014. Available at: [http://www.szjt.gov.cn/xxgk/tjsj/tjfx/201502/t20150228\\_2820587.htm](http://www.szjt.gov.cn/xxgk/tjsj/tjfx/201502/t20150228_2820587.htm). Verified on: August 29, 2016.
  32. Hornberger J, Holodniy M, Robertus K, et al. A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. *Med Decis Making*. 2007;27:789-821.
  33. Kumar M, Birch S, Maturana A, et al. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India. *Health Policy*. 2006;77:233-243.
  34. Owens DK, Nease RF, Jr, Harris RA. Cost-effectiveness of HIV screening in acute care settings. *Arch Intern Med*. 1996;156:394-404.
  35. Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. *AIDS*. 2000;14:2159-2169.
  36. Postma MJ, Beck EJ, Hankins CA, et al. Cost effectiveness of expanded antenatal HIV testing in London. *AIDS*. 2000;14:2383-2389.
  37. Rozenbaum MH, Verweel G, Folkerts DK, et al. Cost-effectiveness estimates for antenatal HIV testing in the Netherlands. *Int J STD AIDS*. 2008;19:668-675.
  38. Zaric GS, Bayoumi AM, Brandeau ML, et al. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. *J Acquir Immune Defic Syndr*. 2000;25:403-416.
  39. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes (3rd edition). *Oxford University Press*. 2005.
  40. Huang X, Lodi S, Fox Z, et al. Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. *J Acquir Immune Defic Syndr*. 2013;62:441-446.
  41. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. *N Engl J Med*. 2005;352:586-595.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Figure 1. Folow chart of recruitment

Figure 2. Folow chart of study procedure

Table 1. Schematic diagram of study procedure

Procedure	Timeline										
	D-180	D1	D2	D30*	D180	D190	D240	D300	D360	D370	D540
Logistics preparation	√										
Enrolment and allocation		√									
Message A sent to both arms		√									
Message B sent to intervention arm			√								
Message C sent to intervention arm				√	√				√		
Message D sent to both arms					√						
Message E sent to both arms									√		
M6 follow-up of both arms						√					
M12 follow-up of both arms										√	
Baseline data analysis								√			
Interim data analysis									√		
Follow-up data analysis											√

Notes:

D refers to day, D-180 means 180 days before enrolment.

\* Beginning from day 30, Message C will be sent to intervention arm every 30 days until day 360.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Flow chart of recruitment

Figure 1  
83x40mm (300 x 300 DPI)

er review only




Figure 2. Flowchart of study procedure

Figure 2

109x68mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





# UNSW Human Research Ethics Application Form

More than Low Risk OR Low Risk Research Applications

## Project Description Template

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60</p>	<p><b>1. Lay Summary &amp; Aims (Maximum of 500 words)</b></p> <p>Briefly provide a summary of the project in lay terminology (no more than 500 words). The project summary should include the following details:</p> <ul style="list-style-type: none"> <li>• Aims of the project</li> <li>• Importance of the study</li> </ul> <p>Our study aims to use a randomized controlled trial (RCT) to evaluate the role of sexual health clinic (SHC)-based automated short message service (SMS) reminders in the testing and detection of HIV and other sexually transmitted infections (STIs) among men who have sex with men (MSM) in China.</p> <p>At baseline, all male clients will be given an information flyer by a receptionist who is not directly involved in the study. The flyer includes the basic information about the study. Participants will then read the information, decide whether they might meet the inclusion criteria and decide whether they would like to participate. Potentially eligible participants who are willing and able to participate will be guided by the receptionist to a private clinic room where they will see the full Participant Information and Consent Form (PICF) for the study on an iPad. Consented participants will complete a questionnaire on the iPad. Eligibility will be judged by the pre-programmed logic in the questionnaire. After these steps, our research assistant will take eligible participants to see a doctor for biospecimen collection, followed by routine clinical care, in necessary.</p> <p>Eligible participants will be randomly allocated by the computer to either intervention group where they will receive monthly SMS reminders to test for HIV/STIs, or control group where they will not receive such reminders. At 6 and 12 months, participants in both groups will complete an online questionnaire and an onsite questionnaire, respectively, about sexual behaviours, HIV/STI testing behaviours and diagnosis history and alcohol/tobacco/drug use in the past 6 months. Participants in the intervention groups will also be asked about their experiences of SMS reminders in the past 6 months. At baseline and 12 months, an anal swab sample, a urine sample and a blood sample will be collected to test for gonorrhoea, chlamydia, syphilis and HIV. Anogenital warts will also be checked by a clinician.</p> <p>The primary outcome is the rate of HIV/STI testing in the past 12 months will be compared between the two groups. Secondary outcomes include the impact of intervention on sexual health behaviours and cost-effectiveness of intervention.</p> <p>This study is the first to examine the role of SHC-based automated SMS reminders in the testing and detection of HIV/STIs in MSM in China. Findings from this study has the potential to help health authorities to develop new interventional strategies to control HIV/STIs among MSM in China. The intervention, from identifying target population to sending text message reminders, is wholly automated and requires limited human input, which can potentially be easily replicated in other SHCs in China and beyond.</p> <p><b>2. Background Literature Review – (Maximum of 500 words)</b></p> <p>Provide an outline of the theoretical background for the research proposal with reference to relevant literature.</p> <ul style="list-style-type: none"> <li>• The background literature review should be "based on a thorough study of the current literature, as well as previous studies" (NS 1.1c) along with;</li> <li>• The potential significance of the study</li> </ul> <p>MSM in many countries are disproportionately affected by HIV and other STIs [1-4]. More frequent screening has the potential to improve detection of these largely asymptomatic infections, interrupting transmission and improving disease control [5]. Guidelines in a number of countries call for regular screening for HIV/STIs among MSM. For example, the US and Australian guidelines recommend that all MSM be screened for urethral and rectal chlamydia, pharyngeal and rectal gonorrhoea, syphilis and HIV at least once a year, with 3-6 monthly screening of MSM at higher-risk for HIV/STIs transmission [6, 7]. However, available data suggest that the rate of screening for these infections among MSM is much lower than recommended in many countries [8, 9].</p> <p>Significant increases in screening rates for gonorrhoea and chlamydia (Odds ratio (OR) range:1.4-1.9) have been demonstrated in observational studies using several different strategies: use of a computer</p>
---	--





# UNSW Human Research Ethics Application Form

More than Low Risk OR Low Risk Research Applications

1 alert on an electronic medical record [10], the introduction of clinic guidelines on STI screening [11],  
 2 and short text messaging reminders for repeat STI screening [12]. Increases in syphilis testing (OR  
 3 range: 2.3-21.4) were found using the following strategies: advocating regular serological screening for  
 4 syphilis during routine HIV care [13]; including syphilis serology testing routinely with blood tests  
 5 performed as part of HIV monitoring [14]; use of a computer alert on an electronic medical record [15];  
 6 and an electronic medical record system with a reminder to clinicians to enhance syphilis retesting  
 7 following syphilis treatment [16]. A before-and-after study in Australia using existing clinical and  
 8 behavioral data of clients attending a major sexual health clinic (SHC) found that automated, computer-  
 9 generated short message service (SMS) 3-monthly reminders doubled the testing rate for HIV, syphilis,  
 10 gonorrhoea and chlamydia among MSM [17]. That study also demonstrated an increased detection rate  
 11 for syphilis, gonorrhoea and chlamydia, but not for HIV [17]. Another before-and-after study in  
 12 Australia found increased HIV/STI re-testing rates among MSM as a result of 3-6 monthly SMS  
 13 reminders at a large SHC [12]. However until now there has been no randomized controlled trial to  
 14 confirm these effects.

15  
 16  
 17  
 18  
 19  
 20  
 21 MSM in China are increasingly engaging in high risk sexual behaviors such as low rate of condom  
 22 use in anal sex, multiple concurrent partnerships and drug use during sex [18]. The rates of HIV and  
 23 STIs among this population are high and increasing. The estimated HIV prevalence among MSM in  
 24 China increased sharply over the past decade: from 0.6% in 2003 to 8% in 2015 [19, 20]. Accordingly  
 25 the proportion of MSM among all people living with HIV/AIDS also climbed steadily: from 7% in 2005  
 26 to 25% in 2015 [21, 22]. Many MSM in China were also infected with other STIs. A meta-analysis  
 27 found that the prevalence levels of STIs among MSM in China were 6% for chlamydia, 2% for genital  
 28 warts, 2% for gonorrhoea, 9% for hepatitis B, 1% for hepatitis C, 66% for human papillomavirus and  
 29 11% for herpes simplex virus-2 [23]. However the testing rate for these infections was suboptimal. A  
 30 systematic review found that less than 40% of MSM in China had tested for HIV in the past year [24].  
 31 Nearly half of MSM in China had a baseline CD4+ Cell count  $\leq$  350 per mm<sup>3</sup> at HIV diagnosis [25].  
 32 The rates of testing for other STIs were also low [26, 27]. It is urgently needed to introduce an effective  
 33 intervention that can increase testing and help achieve timely diagnosis of HIV and other STIs among  
 34 MSM in China.

35  
 36  
 37 Findings from this study has the potential to help health authorities to develop new interventional  
 38 strategies to control HIV/STIs among MSM in China. This interventional model can potentially be  
 39 easily replicated in other SHCs in China and beyond.

## References:

- 40 1. Public Health Laboratory System. Increased transmission of syphilis in Brighton and Greater Manchester among men who  
 41 have sex with men. *CDR Wkly* 2000;10:383-386.
- 42 2. Victorian Department of Human Service. Sexually transmissible infections. *Victorian Infectious Diseases Bulletin*  
 43 2007;10:16-22. Available at: [http://www.health.vic.gov.au/\\_data/assets/pdf\\_file/0018/48222/vidbv10i1.pdf](http://www.health.vic.gov.au/_data/assets/pdf_file/0018/48222/vidbv10i1.pdf).  
 44 Accessed 23 June, 20119.
- 45 3. Vodstrcil LA, Fairley CK, Fehler G, Leslie D, Walker J, Bradshaw CS, *et al*. Trends in Chlamydia and Gonorrhoea Positivity  
 46 among Heterosexual Men and Men who have sex with Men attending a large urban sexual health service in  
 47 Australia, 2002-2009. *BMC Infect Dis* 2011;11:158.
- 48 4. Zhang L, Chow EP, Jing J, Zhuang X, Li X, He M, *et al*. HIV prevalence in China: integration of surveillance data and a  
 49 systematic review. *Lancet Infect Dis* 2013;13:955-963.
- 50 5. Zou H, Fairley CK, Guy R, Chen MY. The efficacy of clinic-based interventions aimed at increasing screening for bacterial  
 51 sexually transmitted infections among men who have sex with men: a systematic review. *Sex Transm Dis*  
 52 2012;39:382-387.
- 53 6. Australian Sexually Transmitted Infection and HIV Testing Guidelines for Asymptomatic Men Who Have Sex with Men  
 54 2014. Available at: [http://stipu.nsw.gov.au/wp-content/uploads/STIGMA\\_Testing\\_Guidelines\\_Final\\_v5.pdf](http://stipu.nsw.gov.au/wp-content/uploads/STIGMA_Testing_Guidelines_Final_v5.pdf). Verified  
 55 on March 5, 2015.
- 56 7. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep* 2010;59:1-110.
- 57 8. Hoover JB, Tao G, Heffelfinger JD. Monitoring HIV testing at visits to emergency departments in the United States: very-  
 58  
 59  
 60



# UNSW Human Research Ethics Application Form

More than Low Risk OR Low Risk Research Applications

low rate of HIV testing. *J Acquir Immune Defic Syndr* 2013,**62**:90-94.

9. Adam PC, de Wit JB, Toskin I, Mathers BM, Nashkoev M, Zablotska I, *et al.* Estimating levels of HIV testing, HIV prevention coverage, HIV knowledge, and condom use among men who have sex with men (MSM) in low-income and middle-income countries. *J Acquir Immune Defic Syndr* 2009,**52 Suppl 2**:S143-151.
10. Lister NA, Smith A, Fairley CK. Introduction of screening guidelines for men who have sex with men at an STD clinic, the Melbourne Sexual Health Centre, Australia. *Sex Health* 2005,**2**:241-244.
11. Ryder N, Bourne C, Rohrsheim R. Clinical audit: adherence to sexually transmitted infection screening guidelines for men who have sex with men. *Int J STD AIDS* 2005,**16**:446-449.
12. Bourne C, Knight V, Guy R, Wand H, Lu H, McNulty A. Short message service reminder intervention doubles sexually transmitted infection/HIV re-testing rates among men who have sex with men. *Sex Transm Infect* 2011,**87**:229-231.
13. Cohen CE, Winston A, Asboe D, Boag F, Mandalia S, Azadian B, *et al.* Increasing detection of asymptomatic syphilis in HIV patients. *Sex Transm Infect* 2005,**81**:217-219.
14. Bissessor M, Fairley CK, Leslie D, Howley K, Chen MY. Frequent screening for syphilis as part of HIV monitoring increases the detection of early asymptomatic syphilis among HIV-positive homosexual men. *J Acquir Immune Defic Syndr* 2010,**55**:211-216.
15. Hotton AL, Gratzner B, Pohl D, Mehta SD. Factors associated with repeat syphilis testing at a large urban LGBT health clinic: Chicago, IL 2002-2008. *Sex Transm Dis* 2010,**38**:205-209.
16. Bissessor M, Fairley CK, Leslie D, Chen MY. Use of a computer alert increases detection of early, asymptomatic syphilis among higher-risk men who have sex with men. *Clin Infect Dis* 2011,**53**:57-58.
17. Zou H, Fairley CK, Guy R, Bilardi J, Bradshaw CS, Garland SM, *et al.* Automated, computer generated reminders and increased detection of gonorrhoea, chlamydia and syphilis in men who have sex with men. *PLoS One* 2013,**8**:e61972.
18. Zou H, Wu Z, Yu J, Li M, Ablimit M, Li F, *et al.* Sexual risk behaviors and HIV infection among men who have sex with men who use the internet in Beijing and Urumqi, China. *J Acquir Immune Defic Syndr* 2010,**53 Suppl 1**:S81-87.
19. Meng X, Zou H, Beck J, Xu Y, Zhang X, Miao X, *et al.* Trends in HIV prevalence among men who have sex with men in China 2003-09: a systematic review and meta-analysis. *Sex Health* 2013,**10**:211-219.
20. China Daily. Gay stigma hindering HIV prevention in China. Available at: [http://m.chinadaily.com.cn/en/2015-12/01/content\\_22596045.htm](http://m.chinadaily.com.cn/en/2015-12/01/content_22596045.htm). Verified on: August 30, 2016.
21. Lu F, Wang N, Wu Z, Sun X, Rehnstrom J, Poundstone K, *et al.* Estimating the number of people at risk for and living with HIV in China in 2005: methods and results. *Sex Transm Infect* 2006,**82 Suppl 3**:iii87-91.
22. China Daily. Gay men hit hard by HIV/AIDS epidemic. Available at: [http://europe.chinadaily.com.cn/china/2015-11/20/content\\_22486775.htm](http://europe.chinadaily.com.cn/china/2015-11/20/content_22486775.htm). Verified on: August 30, 2016.
23. Chow EP, Tucker JD, Wong FY, Nehl EJ, Wang Y, Zhuang X, *et al.* Disparities and risks of sexually transmissible infections among men who have sex with men in China: a meta-analysis and data synthesis. *PLoS One* 2014,**9**:e89959.
24. Zou H, Hu N, Xin Q, Beck J. HIV testing among men who have sex with men in China: a systematic review and meta-analysis. *AIDS Behav* 2012,**16**:1717-1728.
25. Tang H, Mao Y, Shi CX, Han J, Wang L, Xu J, *et al.* Baseline CD4 cell counts of newly diagnosed HIV cases in China: 2006-2012. *PLoS One* 2014,**9**:e96098.
26. Davis A, Best J, Luo J, Van Der Pol B, Dodge B, Meyerson B, *et al.* Risk behaviours, HIV/STI testing and HIV/STI prevalence between men who have sex with men and men who have sex with both men and women in China. *Int J STD AIDS* 2015.
27. Lin L, Nehl EJ, Tran A, He N, Zheng T, Wong FY. Sexually transmitted infection testing practices among 'money boys' and general men who have sex with men in Shanghai, China: objective versus self-reported status. *Sex Health* 2014,**11**:94-96.

### 3. Research Design and Methodology (Maximum 1 page)

Provide an outline of the research design, the study timeline and data collection methods.

This randomized controlled trial will consist of computer-assisted self-interview (CASI) and mobile-phone-based intervention of 600 MSM attending the SHCs affiliated to the Guangdong Provincial Center for Skin Disease and STI Control, the Wuxi Municipal Center for Disease Control and Prevention, and the Nanshan District Center for Chronic Disease Control and Prevention.

#### Study Timeline

The study will be conducted over 21-24 months: 3 months of logistic preparation, 3-6 months of recruitment, 12 months of follow up and 3 months of report preparation.


## Study Methodology

### Recruitment and screening:

The following is a step by step summary of the recruitment method (Fig 1):

1. All male clients presenting to the clinic will be given an information flyer by a receptionist who is not directly involved in the study. The flyer will include basic information about the study, including that it is a study for men who have sex with men. The receptionist will ask each male client to read the flyer and to visit the study research assistant who sits at a nearby desk, if they are interested in finding out more about the study.
2. Those male clients who express interest in participating will see the study research assistant, who will take them to a private clinic room where an iPad questionnaire system is installed.
3. The study research assistant will explain what the study involves and go through the iPad-based full Participant Information and Consent Form (PICF) with potential eligible participants. Participants will have time to read the PICF, to ask questions, and to decide if they will participate in the study.
4. The study research assistant will ask consented participants to complete the iPad-based questionnaire on their own, in the private room. They will be instructed that if they have any further questions, they should ask the research assistant who will be at a desk, outside of the private room.
5. The pre-programmed logic in the questionnaire will judge if a participant is actually eligible, based on sexual behavior variables. Eligible participants will provide a valid mobile phone number and then be automatically randomised into either intervention or control group, by the computer. Those who are not eligible will be thanked and released back into the clinic waiting room for their routine clinical care.
6. Eligible participants will see the study research assistant who guides them to see a doctor for biospecimen collection, followed by routine clinical care, if necessary.

**Figure 1. Flow chart of recruitment**



**Randomization:** Once the participants have completed the questionnaire and judged eligible by the pre-programmed computer logic they will then be randomized by computer to either intervention group (with monthly reminders) or control group (without monthly reminders). MSM who opt out of the study will be recorded and asked about reasons to decline.

**Intervention:** Intervention is a monthly SMS reminder. We acknowledge that directly mentioning of sensitive words such as HIV and STIs in SMS reminders may lead to the exposure of privacy of participants to others. As a result, we will avoid using these sensitive words in actual SMS reminders.



# UNSW Human Research Ethics Application Form

More than Low Risk OR Low Risk Research Applications

Instead, in actual reminders we will use “*Little A*” to refer to “HIV”, “*Little B*” to refer to “STIs”, “*Health check*” to refer to “HIV/STI testing” and “*Self health check*” to refer to “HIV self-testing at home”. We will clarify this in the PICF so participants for they to consent.

## Group A: MSM in the Intervention Group

For MSM in the Intervention Group, upon enrolment, they will receive **Message A**: “A gentle reminder: If you plan to have a *health check* again in the next 12 months, welcome to our center. If you do it elsewhere (including *self-health check*) in the next 12 months, please register the results online at the following link: \*\*\*\*\*. Every time you register we will compensate you with an electronic mobile phone credit of CNY10 (USD1.5). If you change your mobile phone number in the next 12 months please let us know.” When they register online, participants need to enter the mobile phone number that was validated at enrolment and the initial of their surname to enter the questionnaire. This is designed to avoid the exposure of sensitive questions to a non participant. On the second day after enrolment, they will receive **Message B**: “A gentle reminder: *Little A* and *little B* are spreading rapidly and it’s hard to detect by yourself. Your best protection is a regular *health check* (e.g. every 3 months). If you change your mobile phone number please let us know.” Starting from day 30, they will receive **Message C** every 30 days: “A gentle reminder: If you have not had a *health check* in the past 3 months please do so as soon as possible. If you change your mobile phone number please let us know.” On day 190, 10 days after they receive **Message C** on day 180, they will receive **Message D**, reminding them to complete an online survey about their sexual life and testing behaviors in the past 6 months: “A gentle reminder: please complete a survey at the following link at your earliest convenience: \*\*\*\*\*. We will compensate you with an electronic mobile phone credit of CNY50 (USD8). If you change your mobile phone number please let us know.” On day 370, 10 days after they receive **Message C** on day 360, they will receive **Message E**, reminding them to complete an onsite survey about their sexual life and testing behaviors in the past 6 months: “A gentle reminder: please attend our center to complete the final survey. We will compensate you with an electronic mobile phone credit of CNY100 (USD16), together with condoms, lubricant and health booklets. If you change your mobile phone number please let us know.” At enrollment and 12 months men will be tested for HIV, syphilis, urethral and anal chlamydia and gonorrhoea, and examined for anogenital warts. CD4+ testing will be provided for men diagnosed with HIV. HIV/STIs will be treated as per relevant treatment guidelines in China. At 6 and 12 months men will also be asked questions about their experience of the intervention including the impact of the intervention on their everyday life, mental health, sexual health and general health (Figure 2).

## Group B: MSM in the Control Group

MSM in the Control Group will receive **Message A** upon enrolment, **Message D** on day 190 and **Message E** on 370. They will not receive **Messages B** and **C**. They will complete the same questionnaire as men in the intervention group do at enrolment, 6 months and 12 months and test for above-mentioned HIV/STIs at enrolment and 12 months. They will not be asked about their experience of the intervention.

The 10 days’ time gap between **Messages C** and **D** is planned to give men in both groups enough time to attend a SHC upon receiving **Message C**. Besides men’s mobile phone number (compulsory) we will also try to collect other contact information (optional), including email, QQ and WeChat ID (instant online messaging applications frequently used in China). At 6 and 12 months, men will be contacted with the additional contact information if they do not complete a designated survey within 7 days after **Messages D** and **E** are sent. Men who register testing information online or fill in an online questionnaire at 6 months will need to enter their mobile number to access the actual questionnaire. This is designed in case another person oversees the URL address from **Message A**.





# UNSW Human Research Ethics Application Form

More than Low Risk OR Low Risk Research Applications

BMJ Open: first published as 10.1136/bmjopen-2016-015787 on 10 July 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

**Collection and storage of biospecimen samples:** For men in both groups, at enrolment and 12 months, a study nurse will collect a swab from the anal canal to test for anal gonorrhoea and chlamydia, and 10 ml of blood to test to test for HIV and syphilis. Participants will self-collect a urine sample to test for urethral gonorrhoea and chlamydia. Biospecimen collected at a given site will be stored at the corresponding participatory institution. The biospecimen will be stored for 5 years and then disposed of.

The process from commencing CASI to the regular dispatch of the reminders will be entirely automated, requiring no human input. This study has been registered at the Chinese Clinical Trial Registry ([www.chictr.org/en](http://www.chictr.org/en)) and WHO International Clinical Trials Registry Platform ([apps.who.int/trialsearch](http://apps.who.int/trialsearch)), ID: ChiCTR-IOR-16009304.

#### 4. Sample Size (Maximum of 250 Words)

Outline the intended sample size for the project and justify how this will meet the aims of the study.

**Power/sample size**

We used the following formula to calculate sample size:

$$n = \frac{(Z_{\alpha} \sqrt{2pq} + Z_{\beta} \sqrt{p_0q_0 + p_1q_1})^2}{(p_1 - p_0)^2}$$

In this formula,  $Z_{\alpha}$  and  $Z_{\beta}$  represent the Z boundaries under the standard normal distribution;  $p_1$  and  $p_0$  represents proportion of a parameter in the intervention group and control group, respectively;  $p$  equals to the average of  $p_1$  and  $p_0$ ;  $q=1-p$ . We used 2 parameters in the calculation of sample size: (a) proportion of men who have HIV testing during the 12 months after baseline; (b) proportion of men who have condomless anal sex during the 12 months after baseline. We assumed a two-sided hypothesis test with a 5% significance level ( $Z_{\alpha/2}=1.96$ ), a desired power of 90% ( $Z_{\beta}=1.28$ ), and that both groups will have the same number of observations.

Using parameter (a), the rate of HIV testing in the past 12 months among MSM in Wuxi in 2014 was 50% ( $p_0$ ), and this figure was expected to increase to 65% ( $p_1$ ) according to a before-and-after study in Australia [17]. This resulted in a sample size of 225 in each group. Khosropour et al., retained around 70% of MSM for 12 months using bimonthly follow-up surveys through text messages [31]. We will adopt a number of strategies to minimize the loss-to-follow-up rate: educating investigators about the culture in MSM community and develop rapport with participants; verifying mobile number at enrolment; contacting participants on days 190 and 370 using various messaging softwares/apps such as WeChat, QQ, email, etc; and reasonable incentives. Considering a loss-to-follow-up rate of 30%, a sample size of 300 MSM in each group will be needed.

Sample size calculations tools can be found online at:

- <http://powerandsamplesize.com/Calculators/> (quantitative)
- <http://stat.ubc.ca/~rollin/stats/ssize/index.html> (quantitative)
- [http://eprints.ncrm.ac.uk/2273/4/how\\_many\\_interviews.pdf](http://eprints.ncrm.ac.uk/2273/4/how_many_interviews.pdf) (qualitative)

#### 5. Research Participants (Maximum of 500 words)

Describe the characteristics of the participants that you intend to recruit in the study (e.g. inclusion/exclusion criteria, sex, age range of participants).

Inclusion criteria:

- 1) anatomical men aged 18 years or older;
- 2) having over 2 male anal sex partners, or condomless anal sex with a casual male sex partner, or an STI history, in the past 12 months;
- 3) possessing a mobile phone;
- 4) willing to provide informed consent for the collection of demographics, sexual behaviors and HIV/STI testing experiences and biological samples to test for HIV/STIs;
- 5) residing in a study city in the next 12 months or visiting a study city frequently enough to participate



# UNSW Human Research Ethics Application Form

More than Low Risk OR Low Risk Research Applications

1	in the study;
2	
3	
4	6) willing to register testing results if they test elsewhere during the study.
5	
6	
7	<b>6. Recruitment of participants</b>
8	Outline the methods that will be used to recruit participants to the study. The methods in this section should describe:
9	<ul style="list-style-type: none"> <li>• What process(es) will be used to identify potential participants;</li> <li>• How initial contact will be made with potential participants;</li> <li>• How participants will be screened to ensure they meet the inclusion criteria.</li> </ul>
10	
11	At baseline, all male clients will be give an information flyer by a receptionist who is not directly
12	involved in the study. The flyer includes the basic information about the study. Participants will then
13	read the information, decide whether they might meet the inclusion criteria and decide whether they
14	would like to participate. Potentially eligible participants who are willing and able to participate will be
15	guided by the receptionist to a private clinic room where they will see the full Participant Information
16	and Consent Form (PICF) for the study on an iPad. The full PICF includes the background and
17	procedure of study, including randomization of participants (monthly reminders in one group and no
18	reminder in the other group). At this stage men will be informed that they may or may not be eligible to
19	participate in this study. Men will need to click the “Agree” button to consent before completing an
20	iPad-based questionnaire. The questionnaire collects information on sexual behaviours, HIV/STI testing
21	behaviours and diagnosis history and alcohol/tobacco/drug use. Based on the questionnaire, the pre-
22	programed computer system will judge if a man is eligible. Eligible MSM are those who report over 2
23	anal sex partners, or condomless anal sex with a casual sex partner, or an STI history, in the past 6
24	months. Eligible MSM who are willing to participate in the study will be asked to provide a valid mobile
25	phone number that will be verified by a code automatically sent to his phone as a short message, to
26	participate in the trial. Men will then receive a text message with a code as their Study ID. Eligible
27	MSM will then be randomized by pre-programed computer system to either intervention group or
28	control group. After these steps, our research assistant will take eligible participants to see a doctor for
29	biospecimen collection, followed by routine clinical care, in necessary. Eligible MSM who opt out of
30	the study will be recorded and asked about reasons to decline.
31	
32	
33	
34	<b>7. Consent</b>
35	Provide a detailed description of the consent process to include the following:
36	<ul style="list-style-type: none"> <li>• The type of consent that will be sought (e.g. verbal/ written/ return of survey etc.), how and when you will provide consent materials to your potential participants and why this method of consent is appropriate for the participant population.</li> <li>• How, when and to whom participants will indicate their consent and how any real or perceived coercion will be avoided during the consent process.</li> </ul>
37	
38	
39	**if the project involves the use of data already collected and the participants have already provided their consent for this to happen, please attach a copy of the original consent form as evidence.
40	**if you are seeking a waiver of consent, please provide justification. (See the National Statement, Chapters 2.2 and 2.3 for more information).
41	
42	A participant is considered as “consented” if he clicks the “agree” button to participate in the study after
43	reading the PICF on the iPad screen, at baseline. The computer system will record this step. An
44	electronic copy of the consent form will be sent to a participant upon request. This procedure is designed
45	to avoid sensitive content mentioned in the consent form (such as HIV testing) to be seen by others on a
46	paper-based PICF. An electronic copy of the consent form is less likely to be seen by others.
47	
48	
49	We acknowledge that directly mentioning of sensitive words such as HIV and STIs in SMS reminders
50	may lead to the exposure of privacy of participants to others. As a result, we will avoid using these
51	sensitive words in actual SMS reminders. Instead, in actual reminders we will use “ <i>Little A</i> ” to refer to
52	“HIV”, “ <i>Little B</i> ” to refer to “STIs”, “ <i>Health check</i> ” to refer to “HIV/STI testing” and “ <i>Self health</i>
53	<i>check</i> ” to refer to “HIV self-testing at home”. We will clarify this in the PICF so participants for they to
54	consent.
55	
56	
57	<b>8. Reimbursement of Expenses or Incentives to Participate</b>
58	Explain whether there will be any reimbursement of out-of-pocket expenses, financial incentive or other “reward” as a result of participation in the study.
59	
60	Participants will receive health education materials, condoms and lubricant upon completion of the CASI



# UNSW Human Research Ethics Application Form

More than Low Risk OR Low Risk Research Applications

BMJ Open: first published as 10.1136/bmjopen-2016-015787 on 10 July 2017. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

questionnaire at enrolment and 12 months. Participants will receive an electronic mobile phone credit of CNY50 (USD8), CNY50 (USD8) and CNY100 (USD16), upon completion of the surveys at enrolment, 6 months and 12 months. Participants who test elsewhere will receive an additional electronic mobile phone credit CNY 10 (USD 1.5) each time they register testing results online. These reimbursements are designed to compensate participants' time to participate in the study. The minimum hourly pay in the three study cities is approximately CNY20 (USD3).

**9. Risks to participants**

Describe the anticipated risks to the participants, including:

- Whether the benefits outweigh the risks to the participants;
- How will you manage or minimise the risks to participants.

We do not anticipate any significant harm from participating from this project. Some men will be diagnosed with HIV and/or STIs, and this may have an emotional impact however we will refer them to standard treatment and care if necessary.

Men will be asked to answer sensitive and detailed questions about their sexual behaviours however they will be informed about this in the consent form.

**10. Privacy and Confidentiality**

Outline the methods that will be applied to ensure that the privacy of participants is protected during:

- The recording and analyses of data;
- The storage of data;
- Publishing or reporting the information.

All electronic questionnaires, consent forms will be stored in a computer at the information center at GCSDESC as per its common practice. Biospecimen collected at a given site will be stored at the corresponding participatory institution. Data will be entered into a pre-established database with identifiable variables decoded. Data will be shared participatory institutions. Data transfer will be conducted as per data transfer standard operation procedures of both institutions.

**Storage of data - China**

All electronic questionnaires, consent forms will be stored in a password-protected computer at the information center at the Guangdong Provincial Center for Skin Disease and STI Control as per its common practice. The data will be stored in a format that is identifiable. This is designed to match data with individual participants in follow-up visits in this study. However, only the custodian Mr Yunyun Zhu at the Guangdong Provincial Center for Skin Disease and STI Control will have access to the original data. All identifying variables, including name (a pseudonym is ok), initial of participant's surname, mobile phone number and date of birth, will be de-identified before data are transferred to a data analyst in this study. The custodian will ensure that data is stored and managed appropriately and according to the relevant privacy laws. The data custodian will only share data with researchers who are conducting HIV/STI testing related epidemiologic studies and only once these projects have received separate ethics approval from a Human Research Ethics Committee. All identifying variables, including name (a pseudonym is ok), initial of participant's surname, mobile phone number and date of birth, will be de-identified before data sharing. Data will be stored for a period of 5 years and it will then be destroyed. Biospecimen collected at a given site will be stored at the corresponding participatory institution. The T2T Study steering committee will share specimen with future researchers only if they get ethics approval from a valid IRB committee. Samples will be de-identified when sharing with other researchers.

**Storage of data - Australia**

The data will be transferred to UNSW within 6 months after the final survey of the last participant is completed. The data will be stored in a password-protected computer at the HIV Epidemiology and Prevention Program at the Kirby Institute. Dr. Huachun Zou will be the custodian for this data. These data will be destroyed when the data stored in China is destroyed. Biospecimen will not be transferred to Australia.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# UNSW Human Research Ethics Application Form

More than Low Risk OR Low Risk Research Applications

## De-Identification of Data

The individually identifiable variables in the T2T Study include name (a pseudonym is ok), initial of participant's surname, date of birth, patient ID, mobile phone number, QQ number, WeChat ID, email address. In the analysis in the T2T Study, date of birth is required to calculate age, time since first sex, time since last HIV testing, etc. Other identifiable variables are required to match data and contact participants. For future research purposes, only age in years and Study ID will be provided, none of the other identifying variables will appear in the data transferred to other researchers.

## Collection and storage of data for future research purposes (Biospecimens and Samples)

### (a) Data to be stored for research purposes the information should detail the following:

Detailed procedure for data storage is described in Section 10.

### (b) Access to the data for future research purposes, the information provided in this section will need to specify:

For future research purposes, researchers will need to obtain ethics approval and submit a concept sheet detailing the purpose of study and variables required. The request to access data will be reviewed by the steering committee of the T2T Study. The T2T Study steering committee will share specimen with future researchers only if they get ethics approval from a valid IRB committee. In future data sharing, samples will be de-identified and only Study ID will be provided.

## 11. Publications and Dissemination of Results

In this section detail how:

- The research results will be reported to the participants of the study;
- How the research results will be reported/ published;
- How participant confidentiality will be maintained in your reports and/or publications.

HIV/STI testing results will be reported to participants as per HIV/STI testing and treatment guidelines in China. The research data will be aggregated, analysed and published in academic journals and presented at national and international academic conferences. The name and any other identifying variable of individual participants will not be included in any published or publicly-available data.



## Sample patient information and consent form

### 1. What is the research study about?

Over 7% of men who have sex with men (MSM) in China have been infected with HIV, with over 10% infected with syphilis and over 30% infected with gonorrhoea, condyloma and other sexually transmitted infections (STIs). You are cordially invited to participate in a study about HIV/STI testing, jointly conducted by Guangdong Provincial Center for Skin Disease and STI Control, Wuxi Municipal Center for Disease Control and Prevention, Shenzhen Nanshan Center for Chronic Disease Control and Prevention, Sun Yat-sen University and the University of New South Wales. This study aims to understand if automated short message service (SMS) reminders can lead to frequent testing and early diagnosis/treatment among MSM. Your participation will help us to improve HIV prevention strategy for the MSM community.

If you are eligible and willing to participate in this study, you will need to provide a valid phone number that will be verified by a code sent to you via SMS. Participants will be randomly allocated into two groups: one group will receive a testing reminder via SMS every 30 days, while the other group will not receive any reminder.

### 2. Inclusion/Exclusion Criteria

Before you decide to participate in this research project, we need to ensure that it is ok for you to take part. If you have ever had a male sex partner you may be eligible to participate in the study. Your eligibility will be judged by the logic pre-programmed in the questionnaire that you will see, if you agree to participate.

### 3. Do I have to take part in this research study?

Participation in any research project is voluntary. If you do not want to take part, you do not have to. If you decide to take part and later change your mind, you are free to withdraw from the project at any stage.

If you decide you want to take part in the research study, you will be asked to:

- Read the information carefully (ask questions if necessary);
- If you would like to participate, sign the consent form;.

### 4. What does participation in this research require, and are there any risks involved?

If you are eligible and decide to take part in the research study, you will be randomly assigned to either **Group A** (receive monthly reminders to remind you to test for HIV/STIs) or **Group B** (no monthly reminders). We will ask you to complete the following tasks:

#### [Completion of Questionnaires]

Today, the research team will ask you to complete an iPad-based questionnaire. This questionnaire will ask you questions about your socio-demographic characteristics, sexual behaviours, HIV/STI testing and diagnosis experiences, attitudes towards HIV pre-exposure prophylaxis, blood donation experiences, and geo-social networking app use experiences. It should take approximately 15 minutes to complete.

At 6 months, the research team will ask you to complete another online questionnaire. This questionnaire will ask you questions about your experiences in the past 6 months, including sexual behaviours, HIV/STI testing and diagnosis experiences, blood donation experiences, and geo-social networking app use experiences. It should take approximately 10 minutes to complete.

At 12 months, the research team will ask you to come back to this site to complete another iPad-based questionnaire. This questionnaire will ask you questions about your experiences in the past 6 months, including sexual behaviours, HIV/STI testing and diagnosis experiences, blood donation experiences, and geo-social networking app use experiences. It should take approximately 10 minutes to complete.

If you are assigned to **Group A**, at 6 and 12 months you will also be asked questions about your experience of the monthly reminders including the impact of the intervention on

your everyday life, mental health, sexual health and general health. You will not be asked these questions if you are assigned to **Group B**.

We don't expect these questionnaires to cause any harm or discomfort, however if you experience feelings of distress as a result of participation in this study you can let the research team know and they will provide you with assistance. Alternatively lists of services are provided in the contact details below to assist you if necessary.

#### [Collection of biospecimen]

Today, a study nurse will collect the following biospecimen from you: an anal swab, a urine sample and 10ml of blood sample. A doctor will also check ano-genital warts for you. It should take approximately 20 minutes to complete.

At 12 months, in the last survey, the research team will ask you to come back to this site. Besides a questionnaire, a study nurse will collect the following biospecimen from you: an anal swab, a urine sample and 10ml of blood sample. A doctor will also check ano-genital warts for you. It should take approximately 20 minutes to complete.

#### [HIV/STI testing]

Today and at 12 months when you come to this site for the last onsite survey, you will be tested for HIV, syphilis, urethral and anal chlamydia and gonorrhoea, and examined for anogenital warts. CD4+ testing will be provided for you if you are diagnosed with HIV. HIV/STIs will be treated as per relevant treatment guidelines in China.

#### [SMS reminders]

We acknowledge that directly mentioning of sensitive words such as HIV and STIs in SMS reminders may lead to the exposure of privacy of participants to others. As a result, we will avoid using these sensitive words in actual SMS reminders. Instead, in actual reminders we will use "**Little A**" to refer to "HIV", "**Little B**" to refer to "STIs", "**Health check-up**" to refer to "HIV/STI testing", "**Self check-up**" to refer to "HIV self-testing at home" and "health kit" to refer to "condoms/lubes/health manuals".

If you are in **Group A**, after completion of the iPad-based questionnaire you will receive **Message A**: "A gentle reminder: If you plan to have a health check again in the next 12 months, welcome to our center. If you do it elsewhere (including self-health check) in the next 12 months, please register the results online at the following link: \*\*\*\*\*. Every time you register we will compensate you with an electronic mobile phone credit of CNY10 (USD1.5). If you change your mobile phone number in the next 12 months please let us know." Tomorrow, you will receive **Message B**: "A gentle reminder: **Little A** and **Little B** are spreading rapidly and it's hard to detect by yourself. Your best protection is a regular check-up (e.g. every 3 months). If you change your mobile phone number please let us know." Starting from day 30, you will receive **Message C** every 30 days: "A gentle reminder: If you have not had a health check in the past 3 months please do so as soon as possible. If you change your mobile phone number please let us know." On day 190, you will receive **Message D**: "A gentle reminder: please complete a survey at the following link at your earliest convenience: \*\*\*\*\*. We will compensate you with an electronic mobile phone credit of CNY50 (USD8). If you change your mobile phone number please let us know." On day 370, you will receive **Message E**, reminding you to complete an onsite survey about your sexual life and testing behaviours in the past 6 months: "A gentle reminder: please attend our center to complete the final survey. We will compensate you with an electronic mobile phone credit of CNY100 (USD16), together with a health kit. If you change your mobile phone number please let us know."

If you assigned to **Group B**, you will receive **Message A** today, **Message D** on day 190 and **Message E** on 370. You will not receive **Messages B** and **C**.

You are free to withdraw from the SMS reminders by calling our study phone number at any time. You are free to withdraw from the research at any time. If you withdraw from the research we will destroy any information that has already been collected.

1  
2  
3 **5. What are the possible benefits to participation?**

4 We hope to use information we get from this research study to benefit other men who  
5 have sex with men who are at high risk for HIV/STI infection but do not test frequently  
6 enough to get diagnosed on a timely basis. You will benefit from this study with free and  
7 professional HIV/STI counselling and testing services, referral and treatment services if  
8 applicable. You will also get free condoms, lubricant and health manual.

9  
10 **6. What will happen to information about me?**

11 By signing the consent form you consent to the research team collecting and using  
12 information about you for the research study, if you are eligible and willing to participate in  
13 this study. If you provide your permission the research team will store your data in a  
14 password-protected databank for 5 years. The data will be stored in a format where you  
15 will be identifiable. This is designed to match your data with you in follow-up visits in this  
16 study. However, only the custodians listed in the table above will have access to your  
17 original data. All identifying variables, including the initial of your surname, mobile phone  
18 number and date of birth, will be de-identified before data are transferred to a data analyst  
19 in this study. The custodians listed in the table above will ensure that your data is stored  
20 and managed appropriately and according to the relevant privacy laws. The data  
21 custodian will only share your data with researchers who are conducting HIV/STI related  
22 epidemiologic studies and only once these projects have received separate ethics  
23 approval from a Human Research Ethics Committee. All identifying variables, including  
24 initial of your surname, mobile phone number and date of birth, will be de-identified before  
25 data sharing.

26 **7. How and when will I find out what the results of the research study are?**

27 The research team intend to publish and report the results of the research study in a  
28 variety of ways, including academic conferences and journals. All information published  
29 will be done in a way that will not identify you. If you would like to receive a copy of the  
30 results you can let the research team know by adding your email within the consent form.  
31 We will only use these details to send you the results of the research. The results will also  
32 be made available via the school's website: kirby.unsw.edu.au.

33 **8. What if I want to withdraw from the research study?**

34 If you do consent to participate, you may withdraw at any time. You can do so by  
35 completing the 'Withdrawal of Consent Form' which is provided at the end of this document.  
36 Alternatively you can ring the research team and tell them you no longer want to  
37 participate. If you decide to leave the research study, the researchers will not collect  
38 additional information from you. Your decision not to participate will not affect your  
39 relationship with the Guangdong Provincial Center for Skin Disease and STI Control, the  
40 Wuxi Municipal Center for Disease Control and Prevention, the Nanshan District Center  
41 for Chronic Disease Control and Prevention, the Kirby Institute, University of New South  
42 Wales, and the Sun Yat-sen University, Guangzhou

43 **9. What type of data will be stored in this data bank?**

44 With your permission we would like to store the following types of data with the  
45 intention to share it and use it in future research projects.

- 46  Socio-demographic characteristics, including your name (a pseudonym is ok),  
47 initial of your surname, mobile phone number, date of birth, ethnicity, marital  
48 status, educational level, income and profession.
- 49  Sexual behaviours, including anal sex with men and vaginal sex with women  
50 and condom use during these sex.
- 51  HIV/STI testing and diagnosis experiences
- 52  Attitudes towards HIV pre-exposure prophylaxis
- 53  Blood donation experiences
- 54  Geo-social networking app use experiences
- 55  Bio-specimen to test for HIV and other STIs

56 **10. What will happen to my data?**

57 If you provide your permission the research team will store your data in a  
58  
59  
60

password-protected databank. The data stored in a format where you will be identifiable. This is designed to match your data with you in follow-up visits in this study. However, only the custodians listed in the table above will have access to your original data. All identifying variables, including name (a pseudonym is ok), initial of your surname, mobile phone number and date of birth, will be de-identified before data are transferred to a data analyst in this study.

#### 11. Who will have access to my data?

Only the custodians listed in below will ensure that your data is stored and managed appropriately and according to the relevant privacy laws. The data custodian will only share your data with researchers who are conducting HIV/STI testing related epidemiologic studies and only once these projects have received separate ethics approval from a Human Research Ethics Committee. All identifying variables, including name (a pseudonym is ok), initial of your surname, mobile phone number and date of birth, will be de-identified before data sharing.

<b>Data Custodians</b>	<i>Mr. Yunyun Zhu</i>	<i>Guangdong Provincial Center for Skin Disease and STI Control, China</i>
------------------------	-----------------------	--

#### 12. How long will you store my data for?

We intend to store your data for 5 years. After 5 years, the data from the questionnaire will be deleted from the computer system and biospecimen will be disposed of as per biosafety practice in China.

#### 13. Can I withdraw my information from this databank?

If you no longer wish to have your data stored or do not wish to be contacted for research purposes you can withdraw your information by completing the withdrawal of consent form that is attached or by phoning the data custodian and letting them know.

#### 14. What should I do if I have further questions about my involvement in the research study?

The person you may need to contact will depend on the nature of your query. If you want any further information concerning this project or if you have any problems which may be related to your involvement in the project, you can contact the following member/s of the research team.

#### 15. Research Team Contact Details

<b>Name</b>	<i>Dr. Huachun Zou</i>
<b>Position</b>	<i>Research Fellow</i>
<b>Telephone</b>	<i>+61 2 9385 3132 or +86 20 8733 5651</i>
<b>Email</b>	<i>hzou@kirby.unsw.edu.au</i>

#### 16. Support Services Contact Details

We don't expect this study procedure to cause any distress, however if you experience feelings of distress as a result of participation in this study you can let the research team know and they will provide you with assistance. If at any stage during the project you become distressed or require additional support from someone not involved in the research please call:

<b>Name/Organisation</b>	<i>Dr. Weiyang Chen/T2T Project</i>
<b>Position</b>	<i>Research Assistant</i>
<b>Telephone</b>	<i>189 2249 3020</i>
<b>Email</b>	<a href="mailto:T2TStudy@outlook.com">T2TStudy@outlook.com</a>

**What if I have a complaint or any concerns about the research study?**

If you have any complaints about any aspect of the project, the way it is being conducted, then you may contact:

**Complaints Contact**

<b>Position</b>	Human Research Ethics Coordinator
<b>Telephone</b>	+ 61 2 9385 6222
<b>Email</b>	<a href="mailto:humanethics@unsw.edu.au">humanethics@unsw.edu.au</a>
<b>HC Reference Number</b>	HC16803

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	ItemNo	Description	Reported on page No
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	<u>1</u>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	<u>2</u>
	2b	All items from the World Health Organization Trial Registration Data Set	<u>2</u>
Protocol version	3	Date and version identifier	<u>6</u>
Funding	4	Sources and types of financial, material, and other support	<u>21</u>
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	<u>21</u>
	5b	Name and contact information for the trial sponsor	<u>21</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>21</u>



1			
2			
3			
4			
5			
6		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
7			
8			
9			
10			
11	<b>Introduction</b>		
12	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
13			
14			
15			
16		6b	Explanation for choice of comparators
17			
18	Objectives	7	Specific objectives or hypotheses
19			
20	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
21			
22			
23			
24			
25			
26			
27	<b>Methods: Participants, interventions, and outcomes</b>		
28	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
29			
30			
31			
32	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
33			
34			
35			
36	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>N/A</u>
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	<u>13</u>
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>N/A</u>
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>14-17</u>
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	<u>8</u>
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<u>13-14</u>
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>8</u>

**Methods: Assignment of interventions (for controlled trials)**

Allocation:



1				
2				
3				
4				
5				
6	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random	<u>9</u>
7	generation		numbers), and list of any factors for stratification. To reduce predictability of a random	
8			sequence, details of any planned restriction (eg, blocking) should be provided in a	
9			separate document that is unavailable to those who enrol participants or assign	
10			interventions	
11				
12	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially	<u>9</u>
13	concealment		numbered, opaque, sealed envelopes), describing any steps to conceal the sequence	
14	mechanism		until interventions are assigned	
15				
16	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will	<u>9</u>
17			assign participants to interventions	
18				
19	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care	<u>10</u>
20			providers, outcome assessors, data analysts), and how	
21				
22		17b	If blinded, circumstances under which unblinding is permissible, and procedure for	<u>10</u>
23			revealing a participant's allocated intervention during the trial	
24				
25				
26	<b>Methods: Data collection, management, and analysis</b>			
27				
28	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including	<u>17-18</u>
29	methods		any related processes to promote data quality (eg, duplicate measurements, training of	
30			assessors) and a description of study instruments (eg, questionnaires, laboratory tests)	
31			along with their reliability and validity, if known. Reference to where data collection	
32			forms can be found, if not in the protocol	
33				
34		18b	Plans to promote participant retention and complete follow-up, including list of any	<u>17-18</u>
35			outcome data to be collected for participants who discontinue or deviate from	
36			intervention protocols	
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>17-18</u>
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>15</u>
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>16-17</u>
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>15</u>
<b>Methods: Monitoring</b>			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>17-18</u>
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>18</u>
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>N/A</u>
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>N/A</u>
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>18</u>

1			
2			
3			
4			
5	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
6			<u>19</u>
7			
8			
9			
10	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
11			<u>8-9</u>
12			
13		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
14			<u>27</u>
15			
16	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
17			<u>17-18</u>
18			
19			
20	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site
21			<u>21</u>
22			
23	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
24			<u>18</u>
25			
26	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
27			<u>N/A</u>
28			
29			
30	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
31			<u>18</u>
32			
33			
34			
35		31b	Authorship eligibility guidelines and any intended use of professional writers
36			<u>N/A</u>
37		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code
38			<u>18</u>
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

**Appendices**

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>27</u>
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	<u>12</u>

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only

*Correction: A randomised controlled trial to evaluate the impact of sexual health clinic based automated text message reminders on testing of HIV and other sexually transmitted infections in men who have sex with men in China: protocol for the T2T Study*

---

Zou H, Meng X, Grulich A, *et al.* A randomised controlled trial to evaluate the impact of sexual health clinic based automated text message reminders on testing of HIV and other sexually transmitted infections in men who have sex with men in China: protocol for the T2T Study. *BMJ Open* 2017;**7**:e015787. doi: 10.1136/bmjopen-2016-015787

HZ and XM contributed equally to the manuscript and are co first authors. Author name Jinmei Han should be Jinmei Huang.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

*BMJ Open* 2017;**7**:e015787corr1. doi:10.1136/bmjopen-2016-015787corr1



CrossMark